

*Rohera Healthcare & Technology Pvt. Ltd.*



**HEALTH IN YOUR HANDS**

**CREDENTIALS  
&  
PATIENT'S REPORTS**

[www.emedica.in](http://www.emedica.in)

[info@emedica.in](mailto:info@emedica.in)

Pune | Mumbai | Delhi | Bangalore



1. About eMedica .....	Page 03
2. Ethical Papers by Maharashtra Govt DMER & Arogya Bhawan .....	Page 05
3. Clinical Trial Reports by Daffrin Hospital (Maharashtra Govt.) .....	Page 09
4. Calibration Report .....	Page 16
5. Certificates .....	Page 27
6. Recognition .....	Page 32
7. Patent Copy .....	Page 37
8. Patients Path-Lab Reports	
I. BSL Trial Reports at Serum Institute .....	Page 41
II. Random BSL Reports .....	Page 42
III. Random Cholesterol Reports .....	Page 52
IV. HbA1C Reports .....	Page 58
V. Creatinine Reports .....	Page 68
VI. Thyroid Report .....	Page 76
VII. Heart Blockage/Condition Reports .....	Page 78
VIII. Refractive Error Report .....	Page 82
IX. Leukaemia Report .....	Page 84



### **The Hypothesis:**

The universe is all about energy. No matter whether you call the energy chi, prana, electrons, or some other name. the universe is about interactions of energy.

In general, it is observed that frequencies can repair damage tissues and cells within body. This is a primary basis for the therapeutic use of this technology, stimulating tissues at a cellular level. Electrical pulse and frequencies passing through our whole body will have a positive charge to our trillions of cells.

### **Basic cell functions and the effect of Electromagnetic Frequencies:**

Our skin, bones, and organs are composed of tiny cells. The membrane of a healthy cell has both positive and negative charges that are required for the exchange of potassium, sodium, and calcium ions. When cells become distressed from disease, trauma or toxins, they lose their ability to function efficiently. eMedica restores the positive and negative charge in the cell, enabling it to perform its natural functions while speeding tissues recovery.

Everyone's body respond differently to electron pulse waves and different frequencies target specific tissues types. eMedica emits a unique series of pulsed electro fields at precise frequencies targeted on four key tissues types resulting in increased circulation. Reduced inflammation, improve modality, and relieved pain.

All cells need energy to function through the increased motion of ions and electrolytes magnetic cells help cells increase their energy or charge.

Electro fields also affect the charges of the cell membrane, which allows membrane channels to open up.

Resting cells are negatively charged on the inside, while the outside of the cell is more positively charged. The flow of charge across the cell membrane is what generates electrical current.

When a cell is stimulated, It allows positive charges to enter the cell through open ion channels. The inside of the cell then becomes more positively charged, which trigger further electrical current that can turn into electrical pulses, called action potentials. Our bodies use certain patterns if action potentials to initiate the correct movements, thoughts and behaviour.



A disruption in electrical current can lead to illness. eMedica Electro Field therapy can restore the disruption of the electrical current to its normal state, therefore. Helping restore the cells. (Source)

Electric and magnetic fields (EMFs) are invisible areas of energy, often referred to as radiation, that are associated with the use of electrical power and various forms of natural and man-made lighting. EMFs are typically characterized by wavelength or frequency into one of two radioactive categories:

**Non-ionizing:** Low level radiation which is generally perceived as harmless to humans

**Ionizing:** High – level radiation which has the potential for cellular and DNA damage  
Along with the increased voltage, the body also needs the raw materials (power nutrition) to heal. If your body does not have the energy storehouse necessary to produce healing, the voltage in the cells lessens, and when that happens, the body will become diseased. These channels are like doors and windows of a house. By opening cell channels, nutrients are better able to enter the cell and waste is more easily eliminated from the cell. This helps to rebalance and restore optimum cell function. If you restore enough cells, they will all work efficiently. Cells of the same type come together to make tissues and those tissues come together to make organs. So, by restoring or maintaining cellular function, allowing the entire body to function better. We all know that the body ages over time. Maintaining the function of every individual cell at an optimal level every day is an important part of slowing aging.

### **Can eMedica therapy protect me from future illnesses?**

Magnetic fields protect against cell injury by improving circulation, energy and repair process. Magnetic fields balance cells, tissues and bodily functions at very fundamental levels. A key to understanding Energetic Medicine is to understand that each cell is designed to run at a specific voltage and a specific frequency. Generally speaking, disease is caused when cells have too little voltage and are running at too low a frequency. To operate correctly, cells must have both the proper voltage and the proper frequency. Chronic illness is almost always characterized by low voltage and a decrease in the frequency of the affected organs.

Restoration of health must involve correcting both the voltage and the frequency of each cell and providing the nutrition necessary to make good new cells.



# **ETHICAL PAPERS**

## **BY GOVERNMENT OF MAHARASHTRA**







सर्वज्ञानं विद्या



## संचालनालय, वैद्यकीय शिक्षण आणि संशोधन, मुंबई

शासकीय वन फार्मास्युटिकल व रुग्णालय इमारत चौथा मजला, रीट कॉलेज रुग्णालय आवार, पी. डी. रोड, पोस्ट, मुंबई - 400 027  
दुरध्वनी- २२-२२६२०३६९-३६/२२६६२२०२/२६३/५९. संकेतस्थळ: <http://www.med-edu.in> & <http://www.emedica.in>

क.सं.वै.शिवसं/संकीर्ण/eMedica/इलेक्टॉनिक मेडिकल गॅजेट/ 18-31/2029, दिनांक 27/99/2029  
कार्यालयीन आदेश 97317

विषय : The innovative Wellness product \_eMedica.

संदर्भ : सीईओ, रोहेरा हेल्थकेअर अॅन्ड टेक्नॉलॉजी प्रा.लि., पुणे  
यांचे पत्र दिनांक १२/१०/२०२१

प्रस्तुत विषयी संदर्भात पत्रान्वये सीईओ, रोहेरा हेल्थकेअर अॅन्ड टेक्नॉलॉजी प्रा.लि., पुणे यांनी "eMedica" या उत्पादनाचे शासकीय रुग्णालयांमध्ये ट्रायल करण्यास परवानगी मिळणेबाबत विनंती केली आहे.

उक्त प्रस्तावामध्ये पुढील बाबी नमुद करण्यात आल्या आहेत.

१. "eMedica" या उपकरणाची उपयुक्तता

Improves Immunity, Support to reduce Heart blockages, Support to control Diabetes, Support to fight different viral infection, Support to control Hypothyroidism, Improves Blood Circulation, Increase Oxygen saturation, Balance the pH level, Control Cholesterol levels, Control Blood Pressure, Support to control Parkinson's & Paralysis, Prevent Cancer & Metastasis, Support to detox liver and kidney, Support to control Uric acid levels (Gout), Support to reduce lung diseases and Fibrosis of lungs. No side effects, Non invasive, Family device.

२. उक्त उपकरणास अन्न व औषध प्रशासनाची मान्यता मिळण्याकरीता संबंधित कंपनीमार्फत प्रस्ताव सादर करण्यात आलेला आहे.

३. eMedica या उपकरणास NABL Approved, CE, ROHS, ISO Certified असे विविध नामांकीत प्रमाणपत्रे प्राप्त झाली असल्याचे प्रस्तावात नमुद केले आहे.

रोहेरा हेल्थकेअर अॅन्ड टेक्नॉलॉजी प्रा.लि., पुणे यांनी eMedica या इलेक्टॉनिक मेडिकल गॅजेट उपकरणाच्या उपयोगासंदर्भात, अधोरेखित केलेल्या उक्त बाबींच्या पडताळणीसह पुढील नमुद मुद्यांबाबत देखिल स्पष्टता होणे आवश्यक आहे.

- सदरचे उपकरण रुग्णोपचाराच्या दृष्टिने उपयुक्त आहे का ? असल्यास प्रचलित उपचार पध्दतीच्या तुलनेत किती प्रमाणात फायदेशिर आहे ?
- शासकीय रुग्णालयात सदर उपकरणाचा वापर करणे शक्य आहे किंवा कसे ?

यासर्व बाबींचा उहापोह करुन सदर उपकरणाचे आयुर्मान, उपयोग सुलभता इत्यादींच्या परिक्षणात्मक अभ्यासांती अहवाल प्राप्त होणे आवश्यक आहे.

यास्तव eMedica या उत्पादनाचे सर्वांगीन चाचणीअंती अहवाल सादर करण्याकरीता पुढील प्रमाणे तज्ञ समिती गठित करण्यात येत आहे.

- १) डॉ. विद्या नगार, प्राध्यापक (तदर्थ), औषधवैद्यकशास्त्र, ग्रं.शा.वै.म., मुंबई
- २) डॉ. गिता शेट, सहयोगी प्राध्यापक, नेफ्रोलॉजी, ग्रं.शा.वै.म., मुंबई
- ३) डॉ. तेजल वधान (सुरळकर), सहयोगी प्राध्यापक, कामा व अल्वेस रुग्णालय, मुंबई

उपरोक्त समितीने eMedica या इलेक्ट्रॉनिक मेडिकल गॅजेट उपकरणाचे परिक्षण करुन स्वयंस्पष्ट अहवाल १० दिवसांत संचालनालयास सादर करावा.

संचालक,

वैद्यकीय शिक्षण व संशोधन, मुंबई

प्रति,

- १) डॉ. विद्या नगार,  
प्राध्यापक (तदर्थ), औषधवैद्यकशास्त्र, ग्रं.शा.वै.म., मुंबई
- २) डॉ. गिता शेट,  
सहयोगी प्राध्यापक, नेफ्रोलॉजी, ग्रं.शा.वै.म., मुंबई
- ३) डॉ. तेजल वधान (सुरळकर),  
सहयोगी प्राध्यापक, कामा व अल्वेस रुग्णालय, मुंबई

✓ प्रत : सीईओ, रोहेरा हेल्थकेअर अॅन्ड टेक्नॉलॉजी प्रा.लि, पुणे

यांना कळविण्यात येते की, eMedica या उपकरणाचे उक्त समितीसमोर सादरीकरण करावे. तसेच तपासणी/प्रात्यक्षिकाकरीता उपकरणी उपलब्ध करुन द्यावे.

प्रत : माहितीस्तव.

- १) अधिष्ठाता, ग्रॅन्ट शासकीय वैद्यकीय महाविद्यालय, मुंबई
- २) अधिक्षक, कामा व अल्वेस रुग्णालय, मुंबई

 <h2 style="text-align: center;">आरोग्य सेवा आयुक्तालय ,</h2> <h3 style="text-align: center;">(महाराष्ट्र राज्य)</h3> <p style="text-align: center;">आरोग्य भवन, ६वा मजला, सेंट जॉर्ज्स रुग्णालय, आवार, पीडिमेलो रोड, मुंबई ४०० ००१</p>		
कार्यालय	दूरध्वनी	Website : <a href="http://maha-arogya.gov.in">http://maha-arogya.gov.in</a>
आयुक्त, आरोग्य सेवा	२२६२ ०२३५	Email : <a href="mailto:jdhs03@gmail.com">jdhs03@gmail.com</a>
संचालक (वैयक्तिक)	२२६२९००६	
सहसंचालक (रुग्णालये)	२२६९९४७९	१७५-७९
आरोग्य सेवा	क्र.आसेआ/कक्ष-३/टे.३/८५/२१/ई-मिडिका/ १२२ दि. ५ जानेवारी, २०२२	

प्रति,

मे.स्वतंत्र पॉवर प्रा.लि.,

२०१, मनिष प्लाझा, शारामा मॅजिस्ट्रीक,

एन.आय.बी.एम.रोड,

पुणे ४११ ०४८


विषय - ई-मिडिका बाबत...

संदर्भ - आपले दि.२८.७.२०२१ चे पत्र

उपरोक्त विषयी आपणांस कळविण्यांत येते की, आपल्या संदर्भाधीन पत्रान्वये ई-मिडिका या उत्पादनाबाबतचे माहितीपत्रक व इतर कागदपत्रे आयुक्तालयास प्राप्त झालेली आहे. सदरहू पत्रान्वये आपल्या कंपनीने ई-मिडिका हे उपकरण मधुमेह, कॉलेस्ट्रॉल, हृदयविकार, इ. आजारांवर अत्यंत उपयुक्त अस्त्याबाबत कळविले आहे.

तरी आपणांस कळविण्यांत येते की, आपले उपकरण हे विभागीय संदर्भ सेवा रुग्णालय, नाशिक व अमरावती येथे दोन महिन्याकरीता डेमोकरीता बसविण्यांत यावे. तसेच त्याकरीता आवश्यक असलेले मनुष्यबळ आपल्या स्तरावरून उपलब्ध करून देण्यांत यावे.

(मा.आयुक्त महोदय यांची मान्य टिप्पणी)

  
 सहसंचालक, आरोग्य सेवा  
 रुग्णालय (रिजिस्ट्रार), मुंबई

प्रत - वैद्यकीय अधिकांक, विभागीय संदर्भ सेवा रुग्णालय, नाशिक व अमरावती

२/- आपणांस कळविण्यांत येते की, उपरोक्त विषयी ई-मिडिका या उपकरणाचे प्रात्यक्षिक करण्याकरीता सदरहू मशीन आपल्या रुग्णालयामध्ये दोन महिन्याकरीता बसविण्यांत यावे. सदरहू मशीनचा उपयोगिता अहवाल, त्याची किंमत, तसेच रुग्णांना त्याचा होणार फायदा याबाबतचा तज्ञांकडून अहवाल आयुक्तालयास सादर करण्यांत यावा.



प्रत - उपसंचालक, आरोग्य सेवा, नाशिक मंडळ, नाशिक / अकोला मंडळ, अकोला





# **CLINICAL TRIAL REPORT BY GOVERNMENT OF MAHARASHTRA**



  	
Maharashtra Government Health Department <b>Medical Superintendent, Regional Referral Services Hospital,</b> (Daffrin Hospital Campus), Shrikrushana Peth, Amravati-444601	
Ph.No. 0721-2970161, 0721-2970167.	Outward no./RRSH,Amt./MOU / 3244 /2022 Date. 29/6/2022      Email : <a href="mailto:msrrshamt@gmail.com">msrrshamt@gmail.com</a>

To,  
 Rohera Healthcare & Technologies Pvt Ltd  
 E-Medica  
 Pune.

In Regional Referral Services Hospital, Amravati the installation & inauguration of E-Medica device was done in the month of February 2022, since that time patients were enrolled of different diseases as per instructions given by experts of E-Medica.

Total of 132 Covid confirmed cases were enrolled & studied for their improvement in health during this study period. About 60 minutes sessions were given on respective described mode of E-Medica device & parameters like SPO2, Pulse, Temperature, Blood pressure were noted for three different settings.

A total 110 already diagnosed hypertensive patients & 153 diagnosed type II Diabetes mellitus patients were enrolled in study to see the effect of device to minimize blood pressure & blood sugar respectively.

Individual values of baseline (i.e. before use of device) & also values after the use of device on day one, day two & day three were noted in Microsoft excel. Mean and standard deviation were calculated & 't' test were applied using open epi software. After applying 't' test of significance, 'p' value less than 0.05 at 95% confidence interval was considered statistically significant.

From the study conducted in this hospital it was concluded that, use of E-Medica device in covid-19 positive patients is a potent adjuvant to reduce the body temperature, pulse rate & improve the oxygen saturation levels in very short continuance of its utility. Also E-Medica device can be adjuvant to decrease the blood pressure & Blood sugar level in diagnosed hypertensive & diabetic patients.

Above results are due to following reasons as stated in Information Brochure given by the manufacturer of E-Medica-

"After applying eMedica device on the specific program (*as pre-programmed & fed in the device*), with specified frequency, voltage & current, it will Enhance the Cell charge of the organ. This process Improves the function of the Organ, Reduces Blood-Fat, Reduces the chances of Cardiac Arrest, Improves the Blood Circulation. When a mild current is exposed to virus or bacteria it would destroy the Virus & Bacteria in the body. In diabetic patients eMedica device transmits specific Voltages and Frequency with the specific electric charge into the human body. As this 3-dimensional technology passed through the blood stream, it enhances the charge of the  $\beta$ -cell in the pancreas, which in-turn improves the function of the organ helping it to produce more insulin. As a specific combination of Voltages-Frequency-Current is passed through the blood stream, it burns the fat/deposit/plaque from the blood vessel. This allows the

insulin generated from the ( $\beta$ -cell) pancreas to penetrate into the blood cells. As the natural insulin (*produced by  $\beta$ -cell*) reached the blood stream it immediately balances the Blood Sugar Level. Hence controlling Diabetes.” (Reference- [www.emedica.in](http://www.emedica.in), Robera Healthcare & Technology Private Limited ROHERA INC.)

This present pilot study was conducted on a limited sample size, which proved the efficacy on covid positive & hypertensive patients. Currently the study is being in process in large number of groups to see its results on Diabetic & hypertensive Patients. The long term effect of e- medica <sup>Needs to be</sup> is conducted on Diabetic patients to understand better blood sugar control over a long term use. As soon we achieve our desired sample size, we will publish its results.

Detailed results of this study with mean with standard deviation & P value are enclosed with this.

1. Dr. M. R. Mendhe – OSD, RRSB, Amravati.
2. Dr. G. Khobragade – MO, RRSB, Amravati.
3. Dr. Ravi Bushan – Nodal Officer RRSB-Covid, Amravati
4. Dr. V. S. Pawar – MO, RRSB, Amravati.
5. Dr. V. S. Dhande- MO, TBH, Amravati.
6. Dr. Shyam Gawande- MO, RRSB, Amravati

10/06/2022  
 11/05/22  
 P.B.  
 11/05/2022  
 11/05/2022  
 11/05/2022  
 Medical Superintendent  
 RRSB, Amravati  
 Medical Superintendent  
 Regional Referral Services Hospital  
 AMRAVATI.



### COVID-19

**Table No.1: Effect of Emedica device on temperature in covid 19 positive patients (n=132)**

DAY	TEMPARATURE (Mean with SD)		P Value (t test)
	BEFORE	AFTER	
DAY 1	99.99 ± 0.98	97.20 ± 0.88	<0.0000001
DAY 2	99.56 ± 0.64	97.25 ± 0.94	<0.0000001
DAY 3	99.56 ± 0.51	97.61 ± 0.76	<0.0000001

**Table No.2: Effect of Emedica device on oxygen saturation in covid 19 positive patients**

DAY	SPO2 (Mean with SD)		P Value (t test)
	BEFORE	AFTER	
DAY 1	93.12 ± 1.52	96.15 ± 1.19	<0.0000001
DAY 2	94.94 ± 2.68	97.06 ± 1.64	<0.0000001
DAY 3	94.78 ± 2.24	97.48 ± 1.30	<0.0000001

**Table No.3: Effect of Emedica device on pulse rate in covid 19 positive patients**

DAY	PULSE (Mean with SD)		P Value (t test)
	BEFORE	AFTER	
DAY 1	92.09 ± 5.76	84.28 ± 12.51	<0.0000001
DAY 2	94.68 ± 4.91	89.27 ± 7.42	<0.0000001
DAY 3	96.12 ± 4.48	90.53 ± 5.73	<0.0000001

Total 132 covid positive patients were enrolled in research to study the effect of Emedica device on improvement in health status of patients. It was found that mean temperature of covid positive patients get decreases, after a session of 60 minutes duration in a day, also it was found that mean temperature of patients were decreases subsequently on day 2 & 3 after its use and the difference was statistically significant. (P <0.05).

Similarly, one of the crucial parameter in covid patients i.e. oxygen saturation shows drastic increase in SPO2 & the difference was statistically significant. (P<0.05) Mean pulse was also reduced subsequently after the use of Emedica device, & difference was also statistically significant.

Thus, it can be concluded that, use of Emedica devise in covid 19 positive patients can be a potent adjuvant to reduce the body temperature, pulse rate & improve the oxygen saturation in very short continuance of its utility.

### RANDOM BLOOD SUGAR

**Table No.6: Effect of Emedica device on random blood sugar in diagnosed case of diabetes mellitus. (n=153)**

DAY	RANDOM BLOOD SUGAR (Mean with SD)		P Value (t test)
	BEFORE	AFTER	
DAY 1	197.16±20.00	136.84 ± 16.92	<0.000001
DAY 2	185.19 ± 19.75	135.17 ± 16.23	<0.000001
DAY 3	172.90 ± 21.55	126.56 ± 15.58	<0.000001

Total 153 diagnosed cases of Diabetes mellitus type 2 were studied for the effect of Emedica device on blood sugar level & it was found that after a session of Emedica device random blood glucose level get decreases and the difference was statistically significant. (P <0.05)

### BLOOD PRESSURE

**Table No.4: Effect of Emedica device on systolic blood pressure in diagnosed case of hypertension (n=110)**

DAY	SYSTOLIC BLOOD PRESSURE (Mean with SD)		P Value (t test)
	BEFORE	AFTER	
DAY 1	147.73 ± 15.63	125.93 ± 16.45	<0.0000001
DAY 2	139.70 ± 11.55	131.5 ± 13.52	0.000002496
DAY 3	143.30 ± 9.12	133.94 ± 9.73	<0.0000001

**Table No.5: Effect of Emedica device on diastolic blood pressure in diagnosed case of hypertension**

DAY	DIASTOLIC BLOOD PRESSURE (Mean with SD)		P Value (t test)
	BEFORE	AFTER	
DAY 1	90.21 ± 9.87	88.85 ± 13.70	0.3992
DAY 2	84.71 ± 8.00	74.77 ± 6.89	<0.0000001
DAY 3	86.72 ± 7.86	82.68 ± 7.70	0.0001547

Total 110 diagnosed cases of Hypertension were studied to see the effect of Emedica device on its effect on lowering blood pressure. It was found that both systolic and diastolic blood pressure get decreases after the use of Emedica device. Also the difference was statistically significant. (P < 0.05)



# **CALIBRATION REPORT**







**HI PHYSIX LABORATORY INDIA PVT. LTD**

B-32/1/2, MIDC, Ranjangaon, Pune, Maharashtra  
info@hiphysix.com, infohplindia@gmail.com  
Phone : 02138 - 232901, 232902, 232903  
CIN : U74120DL2009PTC194754  
Mobile 1 : +91 7768005400  
Mobile 2 : +91 7768005411  
Mobile 3 : +91 7768005422

**TEST REPORT**

Page No. 1 of 10

**TEST REPORT AS PER :- IS 13450 (Part 1)/ IEC 60601-1**

SRF No.: 21040014

Name & Address of Customer: <b>e-Medica</b> Office No A3/A4/A5 Royal Arcade, Pune Satara Road, Near Shankar Maharaj Math, Pune - 411043	ULR No.: TC510021000000450F Discipline: Electrical Group: Safety Testing Facility Test Report No: HPLI/Test/2104001401 Date of Issue: 04/05/2021 Customer Ref. & Date : 09/04/2021		
	Date of Sample Receipt: 09/04/2021	Start of Test Date: 09/04/2021	End of Test Date: 30/04/2021

**PART A - PARTICULARS OF THE SAMPLE SUBMITTED**

Sample description	e-Medica (Wellness Device)
Grade/ variety/ type/ class/ size etc.	e-Medica (Wellness Device)
Declared values, if any	e-Medica (Wellness Device):- Input Rating: 19.0Vdc, 1.0A AC/DC Adapter:- Input Rating: 100-240Vac, 50/60Hz,0.3A Output Rating: 19.0Vdc,1.0A
Code no., BIS seal and IO's sign, if any	Nil
Batch no., date of manufacture and Brand name	Model No. e-Medica (Wellness Device) Brand Name: e-Medica
Quantity	01
Condition of the sample	Good
Reference specification (s)	IS 13450 (Part 1)/ IEC 60601-1 (Tests have been carried out as per customer request)
Environmental conditions	Temperature (25±5)°C & Relative humidity <70%
Statement of Conformity	N/A
Decision Rule	N/A

**PART B - SUPPLEMENTARY INFORMATION**

- Deviations from the test methods as per relevant specification/ work instructions, if any;
- Details of the drawings, graphs, tables, sketches or photographs as referred in the test report, if any: ANNEXURE A attached
- Testing procedure according to work instruction : HPLI03/Test-Medical/WI-01 to 07
- The Management System is maintained in accordance with IS/ISO/IEC 17025:2017 and testing Standards/ Instruments are traceable to National/ International Standards.

- Notes:
- This report is not to be reproduced wholly or in part without our special permission in writing.
  - This report refers only to the particular sample detailed above.
  - The results reported in this certificate are valid at the time of and under the stipulated conditions of measurement.

Tested by

Checked by

Approved by  
HI PHYSIX LABORATORY INDIA PVT. LTD.

Form No. - HPLI04/EM-100

www.hiphysix.com

Registered Office : B-9/51, Sector-18, Rohini, Delhi - 110089.



### HI PHYSIX LABORATORY INDIA PVT. LTD

B-32/1/2, MIDC, Ranjangaon, Pune, Maharashtra  
info@hiphysix.com, infohplindia@gmail.com  
Phone : 02138 - 232901, 232902, 232903  
CIN : U74120DL2009PTC194754  
Mobile 1 : +91 7768005400  
Mobile 2 : +91 7768005411  
Mobile 3 : +91 7768005422

ULR No.: TCS10021000000450F  
Test Report No.: HPLI/Test/2104001401

#### PART C

#### TEST RESULT

Sr. No.	TESTS WITH CLAUSE REFERENCE	SPECIFIED REQUIREMENTS	IS 13450 (Part 1)/IEC 60601-1 RESULTS	
1.	Power Input Test (Cl.4.11 of IS 13450 (Part 1)/IEC 60601-1)	i) Steady-state measured input of ME Equipment or ME System at rated voltage and at operating settings indicated in instructions for use did not exceed marked rating by more than 10%	See appended Table 4.11	
		ii) -Measurements on ME Equipment or ME System marked with one or more rated voltage ranges made at both upper and lower limits of the range	See appended Table 4.11	
2.	Humidity Preconditioning Treatment (CL5.7 of IS 13450 (Part 1)/IEC 60601-1)	ME Equipment or parts there of affected by climatic conditions were set up completely, or partially, with covers detached and subjected to a humidity preconditioning prior to tests of Clauses 8.7.4 and 8.8.3	Before the test of 8.7.4 & 8.8.3, the humidity preconditioning is performance	
		ME Equipment heated to a temperature between T and T + 4 °C for at least 4 h and placed in a humidity chamber with a relative humidity of 93 % ± 3 % and an ambient within 2 °C of T in the range of + 20 °C to + 32 °C for 48 h	25 degree C 93 %RH	
3.	Leakage Currents And Patient Auxiliary Currents (Cl.8.7 of IS 13450 (Part 1)/IEC 60601-1)	8.7.1	a) Electrical isolation providing protection against electric shock limits currents to values in 8.7.3	See appended Table 8.7
			b) Specified values of Earth leakage, Touch, Patient Leakage, and Patient Auxiliary Currents applied in combination of conditions in appended Table 8.7	See appended Table 8.7
		8.7.2	Allowable values specified in 8.7.3 applied under Single Fault Conditions of 8.1 b), except	See appended Table 8.7
			Where insulation used in conjunction with a Protective Earth Connection, insulation short circuited only under conditions in 8.6.4 b)	See appended Table 8.7
			The only single Fault Condition for Earth Leakage current was interruption of one supply conductor at a time	See appended Table 8.7
			- Leakage currents and patient auxiliary current not measured in single fault condition of short circuiting of one constituent part of double insulation	See appended Table 8.7
			Single fault conditions not applied at same time as special test conditions of maximum mains voltage on applied parts and non- protectively earthed parts of enclosure	See appended Table 8.7

Tested by

Checked by

HI PHYSIX LABORATORY INDIA PVT. LTD.

Approved by





### HI PHYSIX LABORATORY INDIA PVT. LTD

B-32/1/2, MIDC, Ranjangaon, Pune, Maharashtra  
info@hiphysix.com, infohplindia@gmail.com  
Phone : 02138 - 232901, 232902, 232903  
CIN : U74120DL2009PTC194754  
Mobile 1 : +91 7768005400  
Mobile 2 : +91 7768005411  
Mobile 3 : +91 7768005422

ULR No.: TC51002100000450F  
Test Report No.: HPLI/Test/2104001401  
IS 13450 (Part 1)/IEC 60601-1

Sr. No.	TESTS WITH CLAUSE REFERENCE	SPECIFIED REQUIREMENTS	RESULTS
		8.7.3 a) Allowable values in 8.7.3 b), c), and d) measured based on, and are relative to currents in Fig 12 a), or by a device measuring frequency contents of currents as in Fig 12 b):	See appended Table 8.7
		b) allowable values of patient leakage and auxiliary currents are according to tables 3 & 4, and values of a.c. are relative to currents having a frequency not less than 0.1Hz:	See appended Table 8.7
		c) Touch current did not exceed 100 $\mu$ A in normal condition and 500 $\mu$ A in single fault condition	See appended Table 8.7
		d) Earth Leakage Current did not exceed 5 mA in normal condition and 10 mA in single fault condition	See appended Table 8.7
		Higher values of Earth Leakage Current permitted for Permanently Installed ME Equipment connected to a supply circuit supplying only this ME Equipment according to local regulations or IEC 60364-7-710:	See appended Table 8.7
		e) Leakage Currents, regardless of waveform and frequency, did not exceed 10 mA r.m.s. in normal or in single fault condition (measured with a non-frequency-weighted device):	See appended Table 8.7
		8.7.4 Leakage and Patient Auxiliary Currents measurements:	See appended Table 8.7
4.	Temperature Rise Test (Excessive temperatures in ME Equipment) (Cl.11.1 of IS 13450 (Part 1) /IEC 60601-1)	11.1.1 Temperatures on ME Equipment parts did not exceed values in Tables 22 and 23 operating in worst-case normal use at maximum rated ambient operating temperature T	See appended Table 11.1.1
		Surfaces of test corner did not exceed 90 °C	Satisfactory (See appended Table 11.1.1)
		11.1.2 Applied parts (hot or cold intended to supply heat to a patient) comply	Applied part not supply heat to patient
		11.1.2.2 Applied parts not intended to supply heat to a patient complies with the limits of table 24 in both normal condition and single fault condition	Complies (See appended Table 11.1.1)
		Applied parts surface temperature exceeds 41°C disclosed in the instruction manual:	Not exceed 41°C
Applied parts surface temperature of equal to or less than 41°C	See appended Table 11.1.1		
5.	Interruption of Power Supply (Cl.11.8 of IS 13450 (Part 1) /IEC 60601-1)	Interruption and restoration of power supply did not result in a hazardous situation, except interruption of its intended function	Unit operation normally after Interrupted and restored (Equipment state: Loaded, operating mode)

Tested by

Page 03 of 10

Checked by



**HI PHYSIX LABORATORY INDIA PVT. LTD**

B-32/1/2, MIDC, Ranjangaon, Pune, Maharashtra  
info@hiphysix.com, infohplindia@gmail.com  
Phone : 02138 - 232901, 232902, 232903  
CIN : U74120DL2009PTC194754  
Mobile 1 : +91 7768005400  
Mobile 2 : +91 7768005411  
Mobile 3 : +91 7768005422

ULR No.: TCS10021000006450F  
Test Report No.: HPLI/Test/2104001401  
IS 13450 (Part 1)/IEC 60601-1

Sr. No.	TESTS WITH CLAUSE REFERENCE	SPECIFIED REQUIREMENTS	RESULTS	
6.	Abnormal operation & Single Fault Condition (Cl.13 of IS 13450 (Part 1) /IEC 60601-1)	13.1.1	None of hazardous situations in 13.1.2-13.1.4, inclusive, occurred when single fault conditions applied, one at a time, as in 4.7 and 13.2	Satisfactory
		13.1.2	Emission of flames, molten metal, poisonous or ignitable substance in hazardous quantities did not occur	No fire, emission of molten metal or ignition of substances was noted during the tests.
			Temperatures of applied parts did not exceed allowable values in table 24 when measured as in 11.1.3	Complies (See appended Table 11.1.1)
			Temperatures of ME equipment parts that are not applied parts likely to be touched did not exceed values in table 23 when measured and adjusted as in 11.1.3	See appended Table 11.1.1
		13.1.3	Limits for leakage current in single fault condition based on 8.7.3 did not exceed	Complies (See appended Table 8.7)
			Voltage limits for accessible parts including applied parts in 8.4.2 did not exceed	Complies (See appended Table 8.7)
		13.2.1	During application of single fault conditions in 13.2.2 -13.2.13, inclusive, normal conditions in 8.1 a) applied in least favourable combination	Considered.
		13.2.2 to 13.2.12	ME Equipment complied with 13.2.2 -13.2.12	See appended Table 13.2
13.2.13	ME Equipment remained safe after tests of 13.2.13.2 to 13.2.13.4 (inclusive), and cooling down to within 3°C of the temperature in the test environment	See appended Table 13.2		
	For insulation of thermoplastic materials relied upon as a means of protection (see 8.8), the ball pressure test specified in 8.8.4.1 a) performed at a temperature 25 °C higher than temperature of insulation measured during tests of 13.2.13.2 to 13.2.13.4 (inclusive).	Ball-pressure test for nonmetallic enclosure has been carried out at 75°C & found Satisfactory (See appended Table 8.8.4.1)		
7.	Drop test (Cl.15.3.4 of IS 13450 (Part 1) /IEC 60601-1)	15.3.4.2 Sample of portable ME Equipment, accessories and portable part with safe working load lifted to a height as in table 29 above a 50 ± 5 mm thick hardwood board lying flat on a concrete floor or rigid base, dropped 3 times from each orientation in normal use (cm)	There was no damage to the interior or exterior of the tested sample which caused exposure to live parts or increased risk of electric shock	

**PART D:**

- Remarks:**
- The observations given in part A of the cover page of the test report are taken from the marking on the sample and specification given by the customer.
  - All the test covered in this test reports are performed as per Customer request.

Tested by

Checked by  
Page 04 of 10







### HI PHYSIX LABORATORY INDIA PVT. LTE

B-32/1/2, MIDC, Ranjangaon, Pune, Maharashtra  
info@hiphysix.com, infohplindia@gmail.com  
Phone : 02138 - 232901, 232902, 232903  
CIN : U74120DL2009PTC194754  
Mobile 1 : +91 7768005400  
Mobile 2 : +91 7768005411  
Mobile 3 : +91 7768005422

#### ANNEXURE A

ULR No.: TC51002100000450F

Test Report No.: HPLI/Test/2104001401

IS 13450 (Part 1)/IEC 60601-1

8.10 TABLE: List Of Critical Components					
Object/part or Description	Manufacturer/ Trademark	Type/Model	Technical data	Standard (Edition/ year)	Mark(s) of Conformity <sup>1)</sup>
AC/ DC Adapter	Shyam Electronics Magnetics	LT19-SEM-7430	Input :100-240Vac 50/60Hz,0.3A Output: 19Vdc, 1.0A	IS13450 (Part 1)/ IEC60601-1	Tested with appliance
Interconnecting Cable	RR Kabel Limited	Various	PVC 1100V	IS 694	CN/L- 3934068
LCD Display	Shenzhen Jing Handa Electronics, Ltd	JHD204A	5.0V, 1.2mA	IS13450(Part 1)/ IEC60601-1	Tested with appliance
Varistor	TDK Electronics GmbH & Co OG	S14 series	105°C, up to 8kV 30Vrms,35Vdc	IEC 61051-1 IEC 61051-2 IEC 61051-2-2	VDE 40027582
Plastic Enclosure	Various	Various	Plastic, V-1, min. 1.5 thickness, 80°C	UL94	UL

**Supplementary information:** <sup>1)</sup> An asterisk indicates a mark which assures the agreed level of surveillance. See Licenses and Certificates of Conformity for verification.

4.11 TABLE: Power Input						
Operating Conditions / Ratings		Voltage (V)	Frequen cy (Hz)	Current (A)	Power (W or VA)	Power factor (cos φ)
Test on Model e-Medica						
For AC/DC Adapter: (Shyam Electronics Magnetics, Type LT19-SEM-7430)						
Max. normal loaded / 1.0 A		90Vac	50	0.318	22.59	--
Max. normal loaded / 1.0 A		90Vac	60	0.320	22.60	--
Max. normal loaded / 1.0 A		100Vac	50	0.306	22.45	--
Max. normal loaded / 1.0 A		100Vac	60	0.309	22.48	--
Max. normal loaded / 1.0 A		240Vac	50	0.196	22.38	--
Max. normal loaded / 1.0 A		240Vac	60	0.199	22.40	--
Max. normal loaded / 1.0 A		264Vac	50	0.194	22.34	--
Max. normal loaded / 1.0 A		264Vac	60	0.197	22.35	--
Max. normal loaded		19Vdc	--	0.556	10.56	-
Supplementary information:						

*Tested by*  
Tested by

*Checked by*  
Checked by



### HI PHYSIX LABORATORY INDIA PVT. LTD

B-32/1/2, MIDC, Ranjangaon, Pune, Maharashtra  
info@hiphysix.com, infohplindia@gmail.com  
Phone : 02138 - 232901, 232902, 232903  
CIN : U74120DL2009PTC194754  
Mobile 1 : +91 7768005400  
Mobile 2 : +91 7768005411  
Mobile 3 : +91 7768005422

ULR No.: TCS1002100000450F  
Test Report No.: HPLI/Test02104001401  
IS 13450 (Part 1)/IEC 60601-1

8.7 TABLE: Leakage current				
Type of leakage current and test condition (including single faults)	Supply voltage (V)	Supply frequency (Hz)	Measured max. value (µA)	Remarks
<b>Fig. 13 - Earth Leakage (ER)</b>	-	-	-	<b>Maximum allowed values: 5 mA NC; 10 mA SFC</b>
<b>Before Humidity Condition:</b>				
ER, NC	264	60	152.3	S1 = 1, S5 = 1
ER, NC	264	60	157.9	S1 = 1, S5 = 0
ER, SFC (Neutral Open),	264	60	197.5	S1 = 0, S5 = 1
ER, SFC (Neutral Open)	264	60	199.1	S1 = 0, S5 = 0
<b>After Humidity Condition:</b>				
ER, NC	264	60	153.8	S1 = 1, S5 = 1
ER, NC	264	60	157.7	S1 = 1, S5 = 0
ER, SFC (Neutral Open),	264	60	198.4	S1 = 0, S5 = 1
ER, SFC (Neutral Open)	264	60	199.5	S1 = 0, S5 = 0
<b>(with non frequency-weighted device)</b>				
				<b>Maximum allowed values: 10 mA for NC &amp; SFC</b>
<b>Before Humidity Condition:</b>				
ER, NC	264	60	160.1	S1 = 1, S5 = 1
ER, NC	264	60	163.8	S1 = 1, S5 = 0
ER, SFC (Neutral Open),	264	60	201.6	S1 = 0, S5 = 1
ER, SFC (Neutral Open)	264	60	205.7	S1 = 0, S5 = 0
<b>After Humidity Condition:</b>				
ER, NC	264	60	160.8	S1 = 1, S5 = 1
ER, NC	264	60	164.2	S1 = 1, S5 = 0
ER, SFC (Neutral Open),	264	60	201.5	S1 = 0, S5 = 1
ER, SFC (Neutral Open)	264	60	205.4	S1 = 0, S5 = 0
<b>Fig. 14 - Touch Current (TC)</b>	-	-	-	<b>Maximum allowed values: 100 µA NC; 500 µA SFC</b>
<b>MD between Earth and AC/DC Adapter Plastic Enclosure surface (covered with metal foil)</b>				
<b>Before Humidity Condition:</b>				
TC, NC	264	60	7.6	S1 = 1, S5 = 1, S7 = 1
TC, NC	264	60	5.8	S1 = 1, S5 = 0, S7 = 1
TC, SFC (Neutral Open)	264	60	9.1	S1 = 0, S5 = 1, S7 = 1
TC, SFC (Neutral Open)	264	60	9.5	S1 = 0, S5 = 0, S7 = 1
TC, SFC (Ground Open)	264	60	8.3	S1 = 1, S5 = 1, S7 = 0
TC, SFC (Ground Open)	264	60	17.7	S1 = 1, S5 = 0, S7 = 0

Tested by

Page 06 of 10

Checked by





**HI PHYSIX LABORATORY INDIA PVT. LTE**

B-32/1/2, MIDC, Ranjangaon, Pune, Maharashtra  
info@hiphysix.com, infohplindia@gmail.com  
Phone : 02138 - 232901, 232902, 232903  
CIN : U74120DL2009PTC194754  
Mobile 1 : +91 7768005400  
Mobile 2 : +91 7768005411  
Mobile 3 : +91 7768005422

ULR No.: TC510021000000450P  
Test Report No.: HPLI/Test/2104001401  
IS 13450 (Part 1)/IEC 60601-1

Type Of Leakage Current And Test Condition (Including Single Faults)	Supply Voltage (V)	Supply Frequency (Hz)	Measured Max. Value (Ma)	Remarks
<b>After Humidity Condition:</b>				
TC, NC	264	60	8.3	S1 = 1, S5 = 1, S7 = 1
TC, NC	264	60	6.1	S1 = 1, S5 = 0, S7 = 1
TC, SFC (Neutral Open)	264	60	9.5	S1 = 0, S5 = 1, S7 = 1
TC, SFC (Neutral Open)	264	60	9.8	S1 = 0, S5 = 0, S7 = 1
TC, SFC (Ground Open)	264	60	8.8	S1 = 1, S5 = 1, S7 = 0
TC, SFC (Ground Open)	264	60	19.1	S1 = 1, S5 = 0, S7 = 0
Fig.15 - Patient Leakage Current (P) (MD between surface of footprint to earth)	-	-	-	Maximum allowed values: Type B or BF AP: 10 µA NC; 50 µA SFC (d.c. current); 100 µA NC; 500 µA SFC (a.c.) Type CF AP: 10 µA NC; 50 µA SFC (d.c. or a.c. current)
P, NC	264	60	ac<1	S1 = 1, S5 = N
P, NC	264	60	ac<1	S1 = 1, S5 = R
P, SFC	264	60	ac 1.29 µA	S1 = 0, S5 = N
P, SFC	264	60	ac 1.32 µA	S1 = 0, S5 = R
Fig. 16 - Patient leakage current with mains on the F-type applied parts (PM) (MD between External voltage & surface of footprint)				Maximum allowed values: Type B: N/A, Type BF AP: 5000 µA Type CF AP: 50 µA
P, NC	264	60	ac<1	S1 = 1, S5 = N
P, NC	264	60	ac<1	S1 = 1, S5 = R
P, SFC	264	60	ac<1	S1 = 0, S5 = N
P, SFC	264	60	ac<1	S1 = 0, S5 = R
<b>Supplementary information:</b>				
Note 1: For Earth Leakage Current see 8.7.3 d) and 8.7.4.5;				
Note 2: For Touch Current see 8.7.3 c) and 8.7.4.6;				
Note 3: For Patient Leakage Current See 8.7.3 b) and 8.7.4.7				
Note 4: Total Patient Leakage Current values are only relative to equipment with multiple Applied Parts of the same type. See 8.7.4.7 h). The individual applied parts complied with the Patient Leakage Current values.				
Note 5: In addition to conditions indicated in the Table, tests conducted at operating temperature and after humidity preconditioning of 5.7, equipment energized in stand-by condition and fully operating, max rated supply frequency, at 110 % of the max rated mains voltage				
ER - Earth leakage current TC - Touch current P - Patient leakage current PA - Patient auxiliary current IP - Total Patient current PM - Patient leakage current with mains on the applied parts MD - Measuring device				A - After humidity conditioning B - Before humidity conditioning 1 - Switch closed or set to normal polarity 0 - Switch open or set to reversed polarity NC - Normal condition SFC - Single fault condition

Tested by

Checked by



**HI PHYSIX LABORATORY INDIA PVT. LTD**

B-32/1/2, MIDC, Ranjangaon, Pune, Maharashtra  
info@hiphysix.com, infohplindia@gmail.com  
Phone : 02138 - 232901, 232902, 232903  
CIN : U74120DL2009PTC194754  
Mobile 1 : +91 7768005400  
Mobile 2 : +91 7768005411  
Mobile 3 : +91 7768005422

ULR No.: TC510021000000450F  
Test Report No.: HPLI/Test/2104001401

IS 13450 (Part 1)/IEC 60601-1

8.8.4.1	<b>TABLE: Resistance to heat - Ball pressure test of thermoplastic parts</b>		
	Allowed impression diameter (mm) :	≤2 mm	-
	Force (N) :	20	-
Part/material		Test temperature (°C)	Impression diameter (mm)
Plastic Enclosure		75	0.8
Supplementary information:			
The results were less 2 mm. Cracks were visible to the naked eye.			

11.1.1	<b>TABLE: Excessive temperatures in ME Equipment</b>			
Model No. :	See below	--	--	--
Test ambient (°C) :	25.6	--	--	--
Test supply voltage/frequency (V/Hz)(4) :	90V/50Hz	--	--	--
Sr.No.	Thermocouple location(3)	Max allowable temperature <sup>1)</sup> from Table 22, 23 or 24 or RM file for AP(5) (°C)	Max measured temperature(2), (°C)	Remarks
1	PCB	105	31.4	35.8
2	Plastics Enclosure	60	30.9	35.3
3	LCD Display	60	27.9	32.3
4	LCD Display PCB	105	27.4	31.8
5	Applied part	41	26.8	31.2
6	Adapter Enclosure	60	35.8	40.2
7	Internal wire	105	28.7	33.1
8	Metal	56	31.3	35.7
9	Test Corner	90	25.9	30.3
10	Ambient	--	25.6	Shift Trm 30
Supplementary information: <sup>1)</sup> When thermocouples used to determine temperature of windings, limits of Table 22 reduced by 10 °C.				

Tested by

Page 08 of 10

Checked by





**HI PHYSIX LABORATORY INDIA PVT. LTD**

B-32/1/2, MIDC, Ranjangaon, Pune, Maharashtra  
info@hiphysix.com, infohplindia@gmail.com  
Phone : 02138 - 232901, 232902, 232903  
CIN : U74120DL2009PTC194754  
Mobile 1 : +91 7768005400  
Mobile 2 : +91 7768005411  
Mobile 3 : +91 7768005422

ULR No.: TCS1002100000450F  
Test Report No.: HPLE/Test/2104001401

IS 13450 (Part 1)/IEC 60601-1

13.2 TABLE: Single Fault Conditions			
Clause No.	Description of Single Fault Condition	Results observed	Hazardous Situation (Yes/No)
13.2.2	Electrical Single Fault Conditions per Clause 8.1:	-	-
	Output shorted (AC/DC Adapter)	Unit switched off. No hazard. No defect.	No
	Output overload	Output current: 1.48A max. Maximum temperature of the enclosure: 46.8°C at 25.5°C ambient temperature. No hazard. No defect.	No
Supplementary information: - The measured temperatures did not exceed those allowable. See Table 11 for Temperatures obtained during the indicated Abnormal Operation tests. - There was no flame, extensive smoke or melted metal.			

  
Tested by

Page 09 of 10

  
Checked by



www.emedica.in  
info.emedica@gmail.com



HI PHYSIX  
testing & calibration laboratory


HI PHYSIX LABORATORY INDIA PVT. LTD

B-32/1/2, MIDC, Ranjangaon, Pune, Maharashtra  
info@hiphysix.com, infohplindia@gmail.com  
Phone : 02138 - 232901, 232902, 232903  
CIN : U74120DL2009PTC194754  
Mobile 1 : +91 7768005400  
Mobile 2 : +91 7768005411  
Mobile 3 : +91 7768005422

ULR No.: TC510021000000450F  
Test Report No.: HIPLI/Test/2104001401

IS 13450 (Part 1)/IEC 60601-1

Photograph of EUT



Copy of Marking Plate of AC/DC Adapter



Trademark

Tested by

Checked by  
Page No. 10 of 10

HI PHYSIX LABORATORY INDIA PVT. LTD.  
Approved by  
Dr. N. K. Kulkarni  
(General Manager - Electronics Division)

\*\*\*\*\* END OF THE TEST REPORT \*\*\*\*\*



# **CERTIFICATES**





National Accreditation Board for  
Testing and Calibration Laboratories

**CERTIFICATE OF ACCREDITATION**

**HI PHYSIX LABORATORY INDIA PRIVATE LIMITED**

has been assessed and accredited in accordance with the standard

**ISO/IEC 17025:2017**

**"General Requirements for the Competence of Testing &  
Calibration Laboratories"**

for its facilities at

B-32/1/2, MIDC, INDUSTRIAL AREA, RANJANGAON, PUNE, MAHARASHTRA, INDIA

in the field of

**TESTING**

Certificate Number: TC-5100

Issue Date: 19/11/2021

Valid Until: 18/11/2023

This certificate remains valid for the Scope of Accreditation as specified in the annexure subject to continued satisfactory compliance to the above standard & the relevant requirements of NABL.  
(To see the scope of accreditation of this laboratory, you may also visit NABL website [www.nabl-india.org](http://www.nabl-india.org))

Name of Legal Entity : HI PHYSIX LABORATORY INDIA PRIVATE LIMITED

Signed for and on behalf of NABL



N. Venkateswaran  
Chief Executive Officer





# Certificate of Compliance

RoHS Directive (2011/65/EU) of the European Parliament and of the Council on the restriction of use of certain Hazardous Substances in Electrical and Electronic Equipments

**Certificate No. QVA-RLHV-22-1517483**

Name : ROHERA HEALTHCARE AND TECHNOLOGY PVT LTD  
Address : FLAMINGO, 101 RAHEJA GARDENS, WANORIE PUNE-411040, INDIA.  
Product : "MANUFACTURER OF ELECTRONIC MEDICAL DEVICE E-MEDICA"

This is to state that the above mentioned products is in compliance with RoHS Directive (20/95/EC) of the European Parliament and Commission Decision 2005/618/EC on the restriction of use of certain Hazardous Substances [Lead (Pb), Mercury (Hg), Cadmium (Cd), Hexavalent Chromium (Cr6+), Polybrominated biphenyls (PBBs) and Polybrominated Diphenyl ethers (PBDEs)] in Electrical and Electronic Equipments.

**Statement:**  
This certificate declares that the product type/model described above complies with the mentioned above European Standard(s).

**Remarks:**  
This certificate of complies is based on the evaluation of a sample of the above mentioned products. It does not imply and assessment of the mass-production of the product. This certificate holder may use this certificate in connection with the test certification body should be informed (revision of technical file) for any modification or alterations made to the aforementioned product type(s), including design and manufacture and/or extension to the existing scope of application.  
The certificate is valid for three years if the company applies the technical construction file which has been stored QVA office. This certificate includes declaration of manufacturer.  
Certificate remains property of QVA to whom it must be returned upon request. The certificate validity is conditioned by positive results or surveillance audits.

Validity of this certificate can be verified at [www.gaafs.us](http://www.gaafs.us)

<b>Date of Certification</b>	15 <sup>TH</sup> DEC 2022
<b>1<sup>st</sup> Surveillance Due</b>	14 <sup>TH</sup> DEC 2023
<b>2<sup>nd</sup> Surveillance Due</b>	14 <sup>TH</sup> DEC 2024
<b>Certificate Expiry</b> (Subject to the company maintaining its system To the required standard)	14 <sup>TH</sup> DEC 2025



*[Signature]*  
Authorized Signatory





# Certificate of Compliance

We hereby declare that the technical file of product complied with the requirement of directives Medical Devices Directive 93/42/EEC

**Applicants**

Name : ROHERA HEALTHCARE AND TECHNOLOGY PVT LTD

Address : FLAMINGO 101 RAHEJA GARDENS WANORIE PUNE 411040

Product : "MANUFACTURER OF ELECTRONIC MEDICAL DEVICE E-MEDICA"

**Complies with the requirements applicable to it**

The Certification body has performed an audit of the above product quality system covering the design, manufacture and final inspection of the certified product. The quality system has been assessed, approved and is subject to continuous surveillance according to the Medical Devices Directive 93/42/EEC

**This certificate is issued under the following conditions:**

It applies only to the quality system maintained in the manufacture of above referenced models and it does not substitute the design or type-examination procedures, if requested.

1. The certificate remains valid until the manufacturing conditions or the quality systems are changed.
2. The certificate validity is conditioned by positive results or surveillance audits.
3. After fulfilling the relevant EU legislation, the manufacturer shall affix to each device, of the above referenced models.
4. The CE mark as shown above can be used, under the responsibility of the manufacturer, after completion of an EC Declaration of conformity and compliance with all relevant EC Directives. The statement is based on a single evaluation of one sample of above mentioned product. It does not imply an assessment of the whole production.

**Certificate No. QVA-RLHV-22-1517481**

Certificate can be verified at [www.gaafs.us](http://www.gaafs.us)

<b>Date of Certification</b>	15 <sup>TH</sup> DEC 2022
<b>1<sup>st</sup> Surveillance Due</b>	14 <sup>TH</sup> DEC 2023
<b>2<sup>nd</sup> Surveillance Due</b>	14 <sup>TH</sup> DEC 2024
<b>Certificate Expiry</b> (Subject to the company maintaining its system To the required standard)	14 <sup>TH</sup> DEC 2025



*[Signature]*  
Authorized Signatory







# Certificate of Registration

This is to certify that

**ROHERA HEALTHCARE AND TECHNOLOGY PVT LTD**

FLAMINGO, 101 RAHEJA GARDENS, WANORIE PUNE-411040, INDIA.

*has been independently assessed by QVA and is compliance with the requirement of the standard*

**ISO 13485:2016**

**Quality Management System For Medical Devices**

For the following scope of activities

**"MANUFACTURER OF ELECTRONIC MEDICAL DEVICE E-MEDICA"**

Certificate Number: QVA-RLHV-22-1517482

To verify this certificate please visit at [www.gaafs.us](http://www.gaafs.us)

Date of Certification	15 <sup>TH</sup> December 2022
Issuance Date	15 <sup>TH</sup> December 2022
1 <sup>st</sup> Surveillance Due	14 <sup>TH</sup> December 2023
2 <sup>nd</sup> Surveillance Due	14 <sup>TH</sup> December 2024
Re-Certificate Due	14 <sup>TH</sup> December 2025



*[Signature]*  
Authorized Signatory



QVA Certification  
CAB Address : Maryland Avenue, SW Washington, D.C. 20202  
Validity of this certificate is subject to annual surveillance audits to be done successfully  
This certificate is the property of QVA Certification and shall be returned immediately on request  
QVA Certification is an independent Systems Products and Personal assessment Body, QVA Certification is a accredited by GAAFS.US



# RECOGNITION







Presents



## CERTIFICATE OF RECOGNITION

**Healthcare Innovation  
Award – Corporates**

AWARDED TO

eMedica

Rohera Inc.(E Medica)

THIS AWARD IS TO RECOGNISE &  
HONOUR YOUR EXEMPLARY WORK IN THE FIELD  
OF HEALTHCARE, HELD ON 28<sup>TH</sup> JULY 2021

An Initiative of



www.innoserv.group

*Rahul Jain*

**Mr. Rahul Jain**  
MD, InnoServ Group  
Director, ADMH



27<sup>th</sup> September, 2022

**Letter of Recommendation**

To,  
eMedica  
318 Morya Estate  
Veera desai Road,  
Andheri west,  
Mumbai 400102

We are glad to inform that the eMedica Wellness Device used at Department of Physiotherapy, Sports Medicine and Rehabilitation, nanavati Max Super Specialty Hospital for the last 8 months. The device has been used as a part of holistic treatment approach to patients suffering from Chronic pain and Neurological conditions.


The following effects were seen:

- Improvement in Sleep Patterns
- Reduction in muscle cramps

It is an innovative therapeutic device which can be used safely as a part of providing holistic treatment to patients for promotion and improvement of overall quality of life.



Regards,

  
27. Sept. 2022

Dr Ali Irani,

HOD, Physiotherapy, Rehabilitation & Sports Medicine,  
Nanavati Super Specialty Hospital

*Dr. Ali Irani,*

Head of Department  
Physiotherapy & Sports Medicine.



## LNM Group Lions Hospital & Research Centre - Bhuj

*For the People by the People*



To  
 The Team  
 eMedica  
 Rohera Healthcare & Technology Private Limited

Dear Team Members,

It is with immense pleasure I would like to share my feedback while using your device eMedica in my hospital. I appreciate the effort made by your team member Mr. Bhushan Joshi and Mrs. Bhakti Joshi from Kedar Global, who has explained the science & given us the device to use on various patients. We are glad to share that after using the device on various patients we have found promising & positive results. We conducted 30 days trials in our hospital with Mr. Sitaram Salpekar & Mr. Dashrath Kumar. They are the dialysis Technician of LNM Lions Hospital and Research Center. Also few patients were recommended by Lions hospital team who received the treatment and saw the results. We conducted the treatment on them with eMedica Device as per their health conditions.

**Mr. Sitaram Salpekar, 51 years old, a Dialysis Technician** was quite low on energy; could not get proper sleep at night and did not have urge to eat. As prescribed by eMedica Advisor he was given the Immunity program; Detox of Kidney & Liver Program; Virus Infection Program, and finally the Cold & Cough Program. The result we witnessed in 30 days was quite appreciated by the patient & our doctors. He was feeling Energetic, was able to walk for a longer period; Started getting better sleep; Felt hungrier, and water thirst increased. Trial date is from 22th June 2022 to 22th July 2022.

**Mr. Dashrath Kumar, 27 years old, a Dialysis Technician** was not well and on testing we found his platelets were low. So, to begin with we treated him with eMedica and given the Immunity Program and Virus Program. To our surprise his platelets went up from 172000 to 210000 plus and his energy levels were very high. Trial date is from 10th July 2022 to 22th July 2022.

**Ms. Hiral Thakkar, 22 Years old, a dialysis Patient** suffering from Hypertension. After using eMedica she felt better in terms of energy and anxiety. Also, the fluctuation in Hypertension has reduced. Trial date is from 11th July 2022 to 20th July 2022.

**Mr. Paresh Joshi, 47 years old,** suffering from Parathyroid. He used eMedica two times a day- Immunity Program & Thyroid Program. Felt much energized & helped in getting better sleep. Thyroid tests yet to be done. Trial date is on 4th July to 8th July 2022.

**Mrs. Manglaben Makhwana, 50 years old.** Suffering from diabetes.

**Mrs. Vanitaben Savji Patel above 55 years old,** suffering from sciatica,

**Mrs. Dhanbai Bhimji Kerai 69 years old a Dialysis Patient,** suffering from Diabetes, Hypertension, Thyroid, Digestive Gas issue. **Trials are on with them. Yet to discover results.**

The patients are highly satisfied with eMedica usage and they would like to pursue the treatment further.

**Vyoma Mehta**  
 LNM GROUP LIONS' HOSPITAL AND  
 RESEARCH CENTER - BHUJ



**THE REVIVE**  
A Holistic Neuropsychiatric Care

A Unit of  
**CMD HOSPITAL**

**TO WHOM SO EVER IT MAY CONCERN**

I Dr. Mohan Kumar V. have been introduced to eMedica and found the concept quite interesting and since it has all the certification in place I decided to use eMedica on my patients.

On 10<sup>th</sup> of April 2022 I started using eMedica on my patient Mrs. Saraswathi Her right side of the body is paralyzed. She was unable to move her right side at all.

To test the device (after making sure the device has no side effect) I made her use the device regularly for the paralytic program daily 4 hours from 10<sup>th</sup> April 2022 to 30<sup>th</sup> of April 2022.

After using for only 20 days, to my surprise I found excellent results. She can move & lift her right hand. I suggest her to continue the same for few more months to get back to normal.

I highly recommend the device for Paralysis.

6/5/22

**The Revive**  
A Holistic Neuropsychiatric Care  
(A Unit of CMD Hospital)  
# 9, Beside Hebbal Lake, Near V-Lead,  
Hebbal Ring Road, Mysore-570016

0821-2955188 | 81238 29876  
therevivehospital@gmail.com  
therevive.in  
#9, Beside Hebbal Lake,  
Near V-LEAD Hebbal Ring Road  
Mysuru - 570016





# PATENT



(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau

(43) International Publication Date  
18 March 2021 (18.03.2021)



(10) International Publication Number  
**WO 2021/048642 A1**

- (51) International Patent Classification:  
*A61B 5/00* (2006.01)    *A61N 1/36* (2006.01)  
*G16H 50/20* (2018.01)    *A61N 2/00* (2006.01)  
*G16H 20/00* (2018.01)    *A61B 17/00* (2006.01)  
*G16H 10/60* (2018.01)
- (21) International Application Number: PCT/IB2020/055292
- (22) International Filing Date: 05 June 2020 (05.06.2020)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:  
201921036412    10 September 2019 (10.09.2019) IN
- (72) Inventor; and  
 (71) Applicant: **ROHERA, Hemant Karamchand** [IN/IN]:  
101, Flemingo Raheja Gardens, Wanowrie, Pune-Maharashtra 411040 (IN).
- (74) Agent: **DEWAN, Mohan**; R. K. Dewan & Co. Podar Chambers, S. A. Brelvi Road, Fort, Mumbai-, Maharashtra 400001 (IN).
- (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA,

(54) Title: A MEDICAL THERAPEUTIC DEVICE




FIGURE 1

WO 2021/048642 A1

(57) Abstract: The present disclosure relates to the field of medicine and discloses a medical therapeutic device (100) for monitoring and treating medical condition of patients. The device (100) comprises an input unit (102), a plurality of sensors (104a-n), a control unit (106), a waveform generator unit (112), and a coupling means. The input unit (102) receives at least one input from a user. The sensors (104a-n) monitor a plurality of pre-determined parameters associated with the health of a patient generate detection signals based on the monitored parameters. The control unit (106) selects a program based on the input and the detection signals. The waveform generator unit (112) generates a therapeutic signal of pre-determined values of at least one of voltage, current, and frequency based on the selected program for facilitating treatment of medical condition corresponding to the selected program.

**WO 2021/048642 A1** 

SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR,  
TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

- (84) Designated States** (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

**Declarations under Rule 4.17:**

- as to the identity of the inventor (Rule 4.17(i))
- of inventorship (Rule 4.17(iv))

**Published:**

- with international search report (Art. 21(3))
- in black and white; the international application as filed contained color or greyscale and is available for download from PATENTSCOPE






# **PATH-LAB REPORTS OF THE PATIENTS**





**BEFORE & AFTER**

**BLOOD SUGAR LEVEL TRIALS AT SERUM INSTITUTE, PUNE**



Report from Serum Institute  
 Before and After the Use of MediMagic

DIABETIS STUDY

Sr. No	Name	Age	Date	BSL (Glucometer) / mgdl			BSL -Random		Serum Insulin	
				Pre	Post	After 2hrs	I	II	I	II
1	Mr.Prakash D Kothawale	56	17/08/2018	123	94	92	126	96	5.9	3
2	Mr.Sameer Joshi	45	17/08/2018	207	195	153	242	182	12.7	9.3
3	Mr.Jaysing G Misal	61	17/08/2018	194	164	118	234	116	17.2	7.9
4	Mr.Sunil Gaikwad	40	17/08/2018	240	179	134	264	162	16.4	6.6
5	Mr.Aniket K.Tapkir	30	17/08/2018	214	210	188	238	220	5.4	6.1
6	Mr.Milind Dhattrak	46	17/08/2018	243	177	106	88	102		41
7	Mr.Abhijit Pawar	34	17/08/2018	102	100	83	243	86.3	12.2	7.8

medication taken  
 medication taken

# Random BSL - BEFORE



Patient Name	: Mr. AMARJEET SINGH	Collected	: 07/Sep/2020 01:59PM
Age/Gender	: 47 Y 0 M 0 D /M	Received	: 07/Sep/2020 06:02PM
UHID/MR No	: DWKA.0000000014	Reported	: 07/Sep/2020 06:48PM
Visit ID	: DWKAOPV22	Status	: Final Report
Ref Doctor	: Dr.SELF	Client Name	: SL WAKAD
IP/OP NO	:	Patient location	: WAKAD,Pune

### DEPARTMENT OF BIOCHEMISTRY

Test Name	Result	Unit	Bio. Ref. Range	Method
<b>GLUCOSE, RANDOM , SODIUM FLUORIDE PLASMA</b>	<b>449</b>	mg/dL	70 - 140	Glucose oxidase
HBA1C, GLYCATED HEMOGLOBIN , WHOLE BLOOD-EDTA	11.4	%		HPLC
ESTIMATED AVERAGE GLUCOSE (eAG), WHOLE BLOOD-EDTA	280	mg/dL		Calculated

**Comment:**

Reference Range as per American Diabetes Association (ADA):

REFERENCE GROUP	HBA1C IN %
NON DIABETIC ADULTS >18 YEARS	<5.7
AT RISK (PREDIABETES)	5.7 – 6.4
DIAGNOSING DIABETES	>= 6.5
DIABETICS	
- EXCELLENT CONTROL	6 – 7
- FAIR TO GOOD CONTROL	7 – 8
- UNSATISFACTORY CONTROL	8 – 10
- POOR CONTROL	>10

Note: Dietary preparation or fasting is not required.

1. A1C test should be performed at least two times a year in patients who are meeting treatment goals (and who have stable glycemic control).
2. Lowering A1C to below or around 7% has been shown to reduce microvascular and neuropathic complications of type 1 and type 2 diabetes. When mean annual HbA1c is <1.1 times ULN (upper limit of normal), renal and retinal complications are rare, but complications occur in >70% of cases when HbA1c is >1.7 times ULN.
3. Falsely low HbA1c (below 4%) may be observed in patients with clinical conditions that shorten erythrocyte life span or decrease mean erythrocyte age. HbA1c may not accurately reflect glycemic control when clinical conditions that affect erythrocyte survival are present. Fructosamine may be used as an alternate measurement of glycemic control



SIN No:BI04633725, BI04633726

This test has been performed at Apollo Health and Lifestyle Ltd/Reference Regional Lab, Pune

Apollo Health and Lifestyle Limited

ICN - UBS110TG2000PLC115019

Regd. Office #7-1-617/A, 615 & 616, 7th Floor, Imperial Towers, Opp to Amarnagar Metro Station, Amarnagar, Hyderabad- 500083





# Random BSL - AFTER



Patient Name : Mr.AMARJEET SINGH	Collected : 07/Sep/2020 05:16PM
Age/Gender : 47 Y 0 M 0 D /M	Received : 07/Sep/2020 08:36PM
UHID/MR No : DWKA.0000000014	Reported : 07/Sep/2020 08:52PM
Visit ID : DWKAOPV26	Status : Final Report
Ref Doctor : Dr.SELF	Client Name : SL WAKAD
IP/OP NO :	Patient location : WAKAD,Pune

DEPARTMENT OF BIOCHEMISTRY				
Test Name	Result	Unit	Bio. Ref. Range	Method
GLUCOSE, RANDOM , SODIUM FLUORIDE PLASMA	308	mg/dL	70-140	HEXOKINASE



SIN No:BI04634972  
This test has been performed at Apollo Health and Lifestyle Ltd/Reference Regional Lab, Pune

# Random BSL - BEFORE



Patient Name : Mrs.JYOTI KALSI	Collected : 07/Sep/2020 02:03PM
Age/Gender : 47 Y 0 M 0 D /F	Received : 07/Sep/2020 06:02PM
UHID/MR No : DWKA.0000000015	Reported : 08/Sep/2020 02:58PM
Visit ID : DWKAOPV23	Status : Final Report
Ref Doctor : Dr.SELF	Client Name : SL WAKAD
IP/OP NO :	Patient location : WAKAD,Pune

### DEPARTMENT OF BIOCHEMISTRY

Test Name	Result	Unit	Bio. Ref. Range	Method
GLUCOSE, RANDOM , SODIUM FLUORIDE PLASMA	329	mg/dL	70-140	HEXOKINASE

HBA1C, GLYCATED HEMOGLOBIN , WHOLE BLOOD-EDTA	9.6	%		HPLC
ESTIMATED AVERAGE GLUCOSE (eAG) , WHOLE BLOOD-EDTA	229	mg/dL		Calculated

#### Comment:

Reference Range as per American Diabetes Association (ADA):

REFERENCE GROUP	HBA1C IN %
NON DIABETIC ADULTS >18 YEARS	<5.7
AT RISK (PREDIABETES)	5.7 – 6.4
DIAGNOSING DIABETES	>= 6.5
DIABETICS	
· EXCELLENT CONTROL	6 – 7
· FAIR TO GOOD CONTROL	7 – 8
· UNSATISFACTORY CONTROL	8 – 10
· POOR CONTROL	>10

Note: Dietary preparation or fasting is not required.

- A1C test should be performed at least two times a year in patients who are meeting treatment goals (and who have stable glycemic control).
- Lowering A1C to below or around 7% has been shown to reduce microvascular and neuropathic complications of type 1 and type 2 diabetes. When mean annual HbA1c is <1.1 times ULN (upper limit of normal), renal and retinal complications are rare, but complications occur in >70% of cases when HbA1c is >1.7 times ULN.
- Falsely low HbA1c (below 4%) may be observed in patients with clinical conditions that shorten erythrocyte life span or decrease mean erythrocyte age. HbA1c may not accurately reflect glycemic control when clinical conditions that affect erythrocyte survival are present. Fructosamine may be used as an alternate measurement of glycemic control



SIN No:BI04633753,BI04633754

This test has been performed at Apollo Health and Lifestyle Ltd/Reference Regional Lab, Pune

Apollo Health and Lifestyle Limited

(CIN - U85110TG2000PLC115819)

Regd. Office: #7-1-417/A, 613 & 616, 7th Floor, Imperial Towers, Opp to Amrapet Metro Station, Amrapet, Hyderabad- 500038

For more information contact us at : customer.care@apolloediagnostics.in

# Random BSL - AFTER



Patient Name : Mrs.JYOTI KALSI	Collected : 07/Sep/2020 05:27PM
Age/Gender : 47 Y 0 M 0 D /F	Received : 07/Sep/2020 08:36PM
UHID/MR No : DWKA.0000000016	Reported : 07/Sep/2020 08:52PM
Visit ID : DWKAOPV27	Status : Final Report
Ref Doctor : Dr.SELF	Client Name : SL WAKAD
IP/OP NO :	Patient location : WAKAD,Pune

### DEPARTMENT OF BIOCHEMISTRY

Test Name	Result	Unit	Bio. Ref. Range	Method
GLUCOSE, RANDOM , SODIUM FLUORIDE PLASMA	207	mg/dL	70-140	HEXOKINASE



SIN No:BJ04634997

This test has been performed at Apollo Health and Lifestyle Ltd/Reference Regional Lab, Pune

Apollo Health and Lifestyle Limited

ICM - I85110TG2000PLC115B19J

Regd. Office #7-1-877/A, 815 & 816, 7th Floor, Imperial Towers, Close to Amrapet Metro Station, Amrapet, Hyderabad - 500038



# Random BSL - BEFORE



## GADKARI PATHOLOGY ELISA & MICRO BIOLOGY LABORATORY

Dr. Pravin Gadkari  
M.B.B.S., MD (Path)  
Director NRPL &  
Ayush Blood Bank

• Shop No. 26, Upper Ground Floor, Madhu Madhav Towers, Laxmi Bhavan Square, Dharampeth, Nagpur - 10  
Branch : C/o. Dr. Dhondse Hospital, Radke Layout, Balaji Nagar, Hingna Road, MIDC, Nagpur.  
• Tel. No. : 8237067621, 8087045795 | E-mail : gadkaripravin@yahoo.co.in

Name :- Mrs. Vaidehi Tannirwar Age/Sex :- Female

Ref. By :- Self Date :- 20/7/19


SAMPLE NUMBER :- 346

### REPORT ON BIOCHEMISTRY

INVESTIGATION	RESULTS	NORMAL RANGE
Blood Glucose Random (Pre- Trail )	152 mg/dl.	Less than 160 mg/dl.

### REPORT ON HARMONE ESTIMATION

INVESTIGATION	RESULT	NORML RANGE
Insulin (Pre- Trail)	26.7 uU/mL	0 -- 24 uU/mL

  
Dr. Pravin Gadkari  
MD (Path)

Timing : 8.00 A.M. to 9.00 P.M.

Sunday : 8.00 A.M. to 1.00 P.M.

Timing : MIDC Morning 9.00 A.M. to 2.30 P.M. Eve. : 6.30 P.M. to 8.15 P.M.  
Sunday : 9.00 A.M. to 12.00 P.M.

# Random BSL - AFTER



## GADKARI PATHOLOGY ELISA & MICRO BIOLOGY LABORATORY

Dr. Pravin Gadkari  
M.B.B.S., MD (Path)  
Director NRPL &  
Ayush Blood Bank

- Shop No. 26, Upper Ground Floor, Madhu Madhav Towers, Laxmi Bhavan Square, Dharampeth, Nagpur - 10
- Branch : C/o. Dr. Dhondse Hospital, Radke Layout, Balaji Nagar, Hingna Road, MIDC, Nagpur.
- Tel. No. : 8237067621, 8087045795 | E-mail : gadkaripravin@yahoo.co.in

Name :- Mrs. Vaidehi Tannirwar      Age/Sex :- Female  
Ref. By :- Self      Date :- 20/7/19  
SAMPLE NUMBER :- 349 ( Post - Trail )

### REPORT ON BIOCHEMISTRY

<u>INVESTIGATION</u>	<u>RESULTS</u>	<u>NORMAL RANGE</u>
Blood Glucose Random (Post- Trail )	107 mg/dl.	Less than 160 mg/dl.

### REPORT ON HARMONE ESTIMATION

<u>INVESTIGATION</u>	<u>RESULT</u>	<u>NORML RANGE</u>
Insulin (Post - Trail)	14.7 uU/mL	0 -- 24 uU/mL

*P. Gadkari*  
Dr. Pravin Gadkari  
MD (Path)

Timing : 8.00 A.M. to 9.00 P.M.

Sunday : 8.00 A.M. to 1.00 P.M.

Timing : MIDC Morning 9.00 A.M. to 2.30 P.M. Eve. : 6.30 P.M. to 8.15 P.M.  
Sunday : 9.00 A.M. to 12.00 P.M.

**Random BSL - BEFORE**
**GADKARI PATHOLOGY**  
 ELISA & MICRO BIOLOGY LABORATORY

 Dr. Pravin Gadkari  
 M.B.B.S., MD (Path)  
 Director NRPL &  
 Ayush Blood Bank

- Shop No. 26, Upper Ground Floor, Madhu Madhav Towers, Laxmi Bhavan Square, Dharampeth, Nagpur - 10
- Branch : C/o. Dr. Dhondse Hospital, Radke Layout, Balaji Nagar, Hingna Road, MIDC, Nagpur.
- Tel. No. : 8237067621, 8087045795 | E-mail : gadkaripravin@yahoo.co.in

Name :- Mrs. Nandini Paithankar      Age/Sex :- Female  
 Ref. By :- Self      Date :- 21/7/19  
 SAMPLE NUMBER :- 371 ( Pre - Trial )

**REPORT ON BIOCHEMISTRY**

INVESTIGATION	RESULTS	NORMAL RANGE
Blood Glucose Random	227 mg/dl.	Less than 160 mg/dl.

**REPORT ON HORMONE ESTIMATION**

INVESTIGATION	RESULT	NORMAL RANGE
Insulin	47.8 uU/mL	0 -- 24 uU/mL

*P. Gadkari*  
 Dr. Pravin Gadkari  
 MD (Path)

Timing : 8.00 A.M. to 9.00 P.M.

Sunday : 8.00 A.M. to 1.00 P.M.

 Timing : MIDC Morning 9.00 A.M. to 2.30 P.M. Eve. : 6.30 P.M. to 8.15 P.M.  
 Sunday : 9.00 A.M. to 12.00 P.M.



# Random BSL - AFTER



## GADKARI PATHOLOGY ELISA & MICRO BIOLOGY LABORATORY

Dr. Pravin Gadkari  
M.B.B.S., MD (Path)  
Director NRPL &  
Ayush Blood Bank

• Shop No. 26, Upper Ground Floor, Madhu Madhav Towers, Laxmi Bhavan Square, Dharampeth, Nagpur - 10  
Branch : C/o. Dr. Dhondse Hospital, Radke Layout, Balaji Nagar, Hingna Road, MIDC, Nagpur.  
• Tel. No. : 8237067621, 8087045795 | E-mail : gadkaripravin@yahoo.co.in

Name :- Mrs. Nandini Paithankar Age/Sex :- Female  
Ref. By :- Self Date :- 21/7/19  
SAMPLE NUMBER :- 374 ( Post - Trial )

### REPORT ON BIOCHEMISTRY

INVESTIGATION	RESULTS	NORMAL RANGE
Blood Glucose Random	173 mg/dl.	Less than 160 mg/dl.

### REPORT ON HORMONE ESTIMATION

INVESTIGATION	RESULT	NORML RANGE
Insulin	24.4 uU/mL	0 -- 24 uU/mL

*P. Gadkari*

Dr. Pravin Gadkari  
MD (Path)

Timing : 8.00 A.M. to 9.00 P.M.

Sunday : 8.00 A.M. to 1.00 P.M.

Timing : MIDC Morning 9.00 A.M. to 2.30 P.M. Eve. : 6.30 P.M. to 8.15 P.M.

Sunday : 9.00 A.M. to 12.00 P.M.

Scanned by CamScanner

# Random BSL - BEFORE



## GADKARI PATHOLOGY ELISA & MICRO BIOLOGY LABORATORY

Dr. Pravin Gadkari  
M.B.B.S., MD (Path)  
Director NRPL &  
Ayush Blood Bank

• Shop No. 26, Upper Ground Floor, Madhu Madhav Towers, Laxmi Bhavan Square, Dharampeth, Nagpur - 10  
Branch : C/o. Dr. Dhondse Hospital, Radke Layout, Balaji Nagar, Hingna Road, MIDC, Nagpur.  
• Tel. No. : 8237067621, 8087045795 | E-mail : gadkaripravin@yahoo.co.in

Name :- Mrs. Rachana Jain      Age/Sex :- Female  
Ref. By :- Self      Date :- 21/7/19  
SAMPLE NUMBER :- 370 ( Pre - Trial )

### REPORT ON BIOCHEMISTRY

INVESTIGATION	RESULTS	NORMAL RANGE
Blood Glucose Random	167 mg/dl.	Less than 160 mg/dl.

### REPORT ON HORMONE ESTIMATION

INVESTIGATION	RESULT	NORML RANGE
Insulin	20.7 uU/mL	0 -- 24 uU/mL

*P. Gadkari*  
Dr. Pravin Gadkari  
MD (Path)

Timing : 8.00 A.M. to 9.00 P.M.

Sunday : 8.00 A.M. to 1.00 P.M.

Timing : MIDC Morning 9.00 A.M. to 2.30 P.M. Eve. : 6.30 P.M. to 8.15 P.M.  
Sunday : 9.00 A.M. to 12.00 P.M.

# Random BSL - AFTER



## GADKARI PATHOLOGY ELISA & MICRO BIOLOGY LABORATORY

Dr. Pravin Gadkari  
M.B.B.S., MD (Path)  
Director NRPL &  
Ayush Blood Bank

• Shop No. 26, Upper Ground Floor, Madhu Madhav Towers, Laxmi Bhavan Square, Dharampeth, Nagpur - 10  
Branch : C/o. Dr. Dhondse Hospital, Radke Layout, Balaji Nagar, Hingna Road, MIDC, Nagpur.  
• Tel. No. : 8237067621, 8087045795 | E-mail : gadkaripravin@yahoo.co.in


Name :- Mrs. Rachana Jain      Age/Sex :- Female  
Ref. By :- Self      Date :- 21/7/19  
SAMPLE NUMBER :- 373 ( Post - Trial )

### REPORT ON BIOCHEMISTRY

INVESTIGATION	RESULTS	NORMAL RANGE
Blood Glucose Random	146 mg/dl.	Less than 160 mg/dl.

### REPORT ON HORMONE ESTIMATION

INVESTIGATION	RESULT	NORML RANGE
Insulin	18.6 uU/mL	0 -- 24 uU/mL



Dr. Pravin Gadkari  
MD (Path)



# Random Cholesterol BEFORE



## GADKARI PATHOLOGY ELISA & MICRO BIOLOGY LABORATORY

Dr. Pravin Gadkari  
M.B.B.S., MD (Path)  
Director NRPL &  
Ayush Blood Bank

- Shop No. 26, Upper Ground Floor, Madhu Madhav Towers, Laxmi Bhavan Square, Dharampeth, Nagpur - 10
- Branch : C/o. Dr. Dhondse Hospital, Radke Layout, Balaji Nagar, Hingna Road, MIDC, Nagpur.
- Tel. No. : 8237067621, 8087045795 | E-mail : gadkaripravin@yahoo.co.in

Name :- **Dr. Inder Gundecha** Age/Sex :- Male

Ref. By :- Self Date :- 20/7/19

SAMPLE NUMBER :- 357 ( Pre - Trail )

### REPORT ON BIOCHEMISTRY

INVESTIGATION	RESULTS	NORMAL RANGE
Blood Glucose Random	87 mg/dl.	Less than 160 mg/dl.
<b>LIPID PROFILE</b>		
Cholesterol Total	360 mg/dl.	130-250 mg/dl.
HDL	48 mg/dl.	30-70 mg/dl.
LDL	288 mg/dl.	Upto 155 mg/dl.
VLDL	27 mg/dl.	Upto 35 mg/dl.
Sr. Triglycerides	135 mg/dl.	Upto 170 mg/dl.
Chol./HDL Ratio	7.5	Upto 4.5

\* Done on ion selective Analyzer.

### REPORT ON HORMONE ESTIMATION

INVESTIGATION	RESULT	NORML RANGE
insulin	16.1 uU/mL	0 -- 24 uU/mL

Dr. Pravin Gadkari  
MD (Path)

Timing : 8.00 A.M. to 9.00 P.M.

Sunday : 8.00 A.M. to 1.00 P.M.

Timing : MIDC Morning 9.00 A.M. to 2.30 P.M. Eve. : 6.30 P.M. to 8.15 P.M.

# Random Cholesterol AFTER



## GADKARI PATHOLOGY ELISA & MICRO BIOLOGY LABORATORY

Dr. Pravin Gadkari  
M.B.B.S., MD (Path)  
Director NRPL &  
Ayush Blood Bank

• Shop No. 26, Upper Ground Floor, Madhu Madhav Towers, Laxmi Bhavan Square, Dharampeth, Nagpur - 10  
Branch : C/o. Dr. Dhondse Hospital, Radke Layout, Balaji Nagar, Hingna Road, MIDC, Nagpur.  
• Tel. No. : 8237067621, 8087045795 | E-mail : gadkaripravin@yahoo.co.in

Name :- **Dr. Inder Gundecha** Age/Sex :- Male  
Ref. By :- Self Date :- 20/7/19  
SAMPLE NUMBER :- 361 ( Post - Trail )

### REPORT ON BIOCHEMISTRY

INVESTIGATION	RESULTS	NORMAL RANGE
Blood Glucose Random	<b>74</b> mg/dl.	Less than 160 mg/dl.
<b>LIPID PROFILE</b>		
Cholesterol Total	<b>195</b> mg/dl.	130-250 mg/dl.
HDL	<b>52</b> mg/dl.	30-70 mg/dl.
LDL	<b>125</b> mg/dl.	Upto 155 mg/dl.
VLDL	<b>18</b> mg/dl.	Upto 35 mg/dl.
Sr. Triglycerides	<b>92</b> mg/dl.	Upto 170 mg/dl.
Chol/HDL Ratio	<b>3.75</b>	Upto 4.5

\* Done on auto selective Analyzer.

### REPORT ON HORMONE ESTIMATION

INVESTIGATION	RESULT	NORML RANGE
Insulin	7.5 uU/mL	0 -- 24 uU/mL

*P. Gadkari*  
Dr. Pravin Gadkari  
MD (Path)

Timing : 8.00 A.M. to 9.00 P.M.

Sunday : 8.00 A.M. to 1.00 P.M.

Timing : MIDC Morning 9.00 A.M. to 2.30 P.M. Eve. : 6.30 P.M. to 8.15 P.M.

# Random Cholesterol BEFORE



## GADKARI PATHOLOGY ELISA & MICRO BIOLOGY LABORATORY

Dr. Pravin Gadkari  
M.B.B.S., MD (Path)  
Director NRPL &  
Ayush Blood Bank

• Shop No. 26, Upper Ground Floor, Madhu Madhav Towers, Laxmi Bhavan Square, Dharampeth, Nagpur - 10  
Branch : C/o. Dr. Dhondse Hospital, Radke Layout, Balaji Nagar, Hingna Road, MIDC, Nagpur.  
• Tel. No. : 8237067621, 8087045795 | E-mail : gadkaripravin@yahoo.co.in

Name :- **Mrs. Amisha Gundecha** Age/Sex :- Female  
Ref. By :- Self Date :- 20/7/19  
SAMPLE NUMBER :- 358 ( Pre - Trail )

### REPORT ON BIOCHEMISTRY

<u>INVESTIGATION</u>	<u>RESULTS</u>	<u>NORMAL RANGE</u>
Blood Glucose Random	101 mg/dl.	Less than 160 mg/dl.
<u>LIPID PROFILE</u>		
Cholesterol Total	<b>281 mg/dl.</b>	130-250 mg/dl.
HDL	40 mg/dl.	30-70 mg/dl.
LDL	<b>196 mg/dl.</b>	Upto 155 mg/dl.
VLDL	45 mg/dl.	Upto 35 mg/dl.
Sr. Triglycerides	<b>223 mg/dl.</b>	Upto 170 mg/dl.
Chol./HDL Ratio	7.0	Upto 4.5

\* Done on ion selective Analyzer.

### REPORT ON HORMONE ESTIMATION

<u>INVESTIGATION</u>	<u>RESULT</u>	<u>NORML RANGE</u>
Insulin	43.3 uU/mL	0 -- 24 uU/mL

*P. Gadkari*  
Dr. Pravin Gadkari  
MD (Path)

Timing : 8.00 A.M. to 9.00 P.M.

Sunday : 8.00 A.M. to 1.00 P.M.

Timing : MIDC Morning 9.00 A.M. to 2.30 P.M. Eve. : 6.30 P.M. to 8.15 P.M.  
Sunday : 9.00 A.M. to 12.00 P.M.



# Random Cholesterol AFTER



## GADKARI PATHOLOGY ELISA & MICRO BIOLOGY LABORATORY

Dr. Pravin Gadkari  
M.B.B.S., MD (Path)  
Director NRPL &  
Ayush Blood Bank

- Shop No. 26, Upper Ground Floor, Madhu Madhav Towers, Laxmi Bhavan Square, Dharampeth, Nagpur - 10
- Branch : C/o. Dr. Dhondse Hospital, Radke Layout, Balaji Nagar, Hingna Road, MIDC, Nagpur.
- Tel. No. : 8237067621, 8087045795 | E-mail : gadkaripravin@yahoo.co.in

Name :- **Mrs. Amisha Gundecha** Age/Sex :- Female  
Ref. By :- Self Date :- 20/7/19  
SAMPLE NUMBER :- 360 ( Post – Trail )

### REPORT ON BIOCHEMISTRY

<u>INVESTIGATION</u>	<u>RESULTS</u>	<u>NORMAL RANGE</u>
Blood Glucose Random	91 mg/dl.	Less than 160 mg/dl.
<u>LIPID PROFILE</u>		
Cholesterol Total	<b>234 mg/dl.</b>	130-250 mg/dl.
HDL	<b>48 mg/dl.</b>	30-70 mg/dl.
L.DL	<b>156 mg/dl.</b>	Upto 155 mg/dl.
VLDL	<b>30 mg/dl.</b>	Upto 35 mg/dl.
Sr. Triglycerides	<b>151 mg/dl.</b>	Upto 170 mg/dl.
Chol./HDL Ratio	<b>4.87</b>	Upto 4.5

\* Done on Ion selective Analyzer.

### REPORT ON HARMONE ESTIMATION

<u>INVESTIGATION</u>	<u>RESULT</u>	<u>NORML RANGE</u>
Insulin	22.8 uU/mL	0 -- 24 uU/mL

*P. Gadkari*  
Dr. Pravin Gadkari  
MD (Path)

Timing : 8.00 A.M. to 9.00 P.M.

Sunday : 8.00 A.M. to 1.00 P.M.

Timing : MIDC Morning 9.00 A.M. to 2.30 P.M. Eve. : 6.30 P.M. to 8.15 P.M.  
Sunday : 9.00 A.M. to 12.00 P.M.

# Random Cholesterol BEFORE



Patient Name : <b>Mr. JAYENDRA SINGH</b> Age/Gender : 38 Y 0 M 0 D /M UHID/MR No : DPVP.000000718 Visit ID : DPVPOPV1096 Ref Doctor : Dr.SELF IP/OP NO :	Collected : 24/Aug/2018 02:26PM Received : 24/Aug/2018 05:14PM Reported : <b>24/Aug/2018 05:33PM</b> Status : Final Report Client Name : PCC VADGAONSHERI PUNE Client Code : PCC0157
---	---

DEPARTMENT OF BIOCHEMISTRY

Test Name	Result	Unit	Bio. Ref. Range	Method
<b>LIPID PROFILE, SERUM</b>				
TOTAL CHOLESTEROL	<b>269</b>	mg/dL	<200	Enzymatic (CHE/CHO/POD)
TRIGLYCERIDES	<b>258</b>	mg/dL	<150	Enzymatic(Lipase/GK/GPO/POD)
HDL CHOLESTEROL	<b>39</b>	mg/dL	40-60	Direct Measure PEG
NON-HDL CHOLESTEROL	<b>230</b>	mg/dL	<130	Calculated
LDL CHOLESTEROL	<b>178.4</b>	mg/dL	<100	Calculated
VLDL CHOLESTEROL	<b>51.6</b>	mg/dL	<30	Calculated
CHOL / HDL RATIO	<b>6.90</b>		0-4.97	Calculated

**Comment:**  
Reference Interval as per National Cholesterol Education Program (NCEP) Adult Treatment Panel III Report.

	Desirable	Borderline High	High	Very High
TOTAL CHOLESTEROL	< 200	200 - 239	≥ 240	
TRIGLYCERIDES	<150	150 - 199	200 - 499	≥ 500
LDL	Optimal < 100 Near Optimal 100-129	130 - 159	160 - 189	≥ 190
HDL	≥ 60			
NON-HDL CHOLESTEROL	Optimal <130; Above Optimal 130-159	160-189	190-219	>220

Measurements in the same patient can show physiological and analytical variations.  
NCEP ATP III identifies non-HDL cholesterol as a secondary target of therapy in persons with high triglycerides.

\*\*\* End Of Report \*\*\*

DR. SANJAY INGLE  
MBBS, MD (PATIC)



SIN No: B101018788  
This test has been performed at Apollo Health and Lifestyle Lab Reference Regional Lab, Pune


# Random Cholesterol AFTER

PATIENT NAME : **Mr. Jayendra Singh**      AGE: 38 Yrs / M  
 REFERRED BY: Dr. Self      DATE: **25-08-2018**

## BIOCHEMISTRY LIPID PROFILE

Test Name	Value	Unit	Reference Range
T.CHOLESTEROL	<b>206</b>	mg/dl	Upto 200
S.TRIGLYCERIDES	<b>146</b>	mg/dl	25-200
HDL CHOLESTEROL	41	mg/dl	M:30-70; F:35-90
VLDL	29.2	mg/dl	5-40
LDL CHOLESTEROL	<b>135.8</b>	mg/dl	85-130
T.CHOLESTEROL/HDL	<b>5.02</b>	Ratio	3.0-5.0
LDL/HDL	3.31	Ratio	1.5-3.5
NHDL CHOLESTEROL	165	mg/dl	<160

This is only a professional opinion & not a diagnosis. Please Correlate with clinical conditions.  
 Alert !!! 10-12 hours fasting is mandatory for lipid parameters. If not, values might fluctuate.



DR.SAMIR AGARWAL  
 DNB ( PATH )  
 CONSULTANT PATHOLOGIST



# HbA1C- BEFORE



**PATHOLOGY REPORT**  
B. P. CLINICAL LAB SDN. BHD. (152314-H)



BP Clinical Lab (GM)  
Accredited by Joint  
Commission International



SCAN HERE

Patient Name	: <b>FRANCIS DOMINIC FERNANDEZ</b>	Receiving Branch	: SC Taman Megah
Identification	: S2751828A      Age / Gender : 65 year - Male	Barcode	: D822359912 (EC6038145)
Date of Birth	: 06/11/1957      Nationality : Singaporean	Refer/Policy No	:
Client Name	: Walk-in - WALK-IN - Walk-in	Specimen	:
Doctor's Name	: Dr Tan Hai Ning	Collected	: <b>17/11/2022 09:35 AM</b>
Panel Clinic	: Dr Tan Hai Ning -	Received	: 17/11/2022 06:20 PM
		Report ready	: 18/11/2022 10:34 AM

TEST NAME	RESULT	FLAG	UNIT	REFERENCE	METHOD
<b>HBA1C (糖化血紅蛋白)</b>					
HbA1c (NGSP)	<b>8.3</b>	<b>H</b>	%	Normal: < 5.7 Pre-diabetes: 5.7 - 6.2 Diabetes: ≥ 6.3	Enzymatic
HbA1c (IFCC)	<b>67</b>	<b>H</b>	mmol/mol	Normal: < 39 Pre-diabetes: 39 - 44 Diabetes: ≥ 45 (Management of T2DM CPG, 6th Ed.)	Calculated

Validated By : NG SHI MAN - BP CLINICAL LAB SDN BHD (GLENMARIE)  
Final Report Verified By : SHAHIRAH AZZAHARAH ZURAIMI - BP CLINICAL LAB SDN BHD (TAMAN MEGAH)

Page 1 of 1

Disclaimer: The above reference ranges are based on adult population unless otherwise stated. [^] indicates age-specific paediatric reference range.

For diagnostic purposes, all laboratory test results should be used in conjunction with clinical evidence.

For further confirmation, please repeat test with a another fresh specimen, if desired.

Should you have further enquiries, please contact your nearest BP branch or mail us at bphq@bphealthcare.com

BP Healthcare Group @ Glenmarie, Temasya @ Glenmarie, Jalan Pendaftar U1/54, Section U1, Shah Alam, Selangor, Malaysia

# HbA1C- AFTER



**PATHOLOGY REPORT**  
B. P. CLINICAL LAB SDN. BHD. (152314-H)



Patient Name	: FRANCIS DOMINIC FERNANDEZ	Receiving Branch	: SC Taman Megah
Identification	: S2751828A      Age / Gender : 65 year - Male	Barcode	: D822412740 (EC6099282)
Date of Birth	: 06/11/1957      Nationality : Singaporean	Refer/Policy No	:
Client Name	: Walk-in - WALK-IN - Walk-in	Specimen	: Fasting
Doctor's Name	: Dr Koay Weng Kuan	Collected	: 17/12/2022 10:34 AM
Panel Clinic	: Dr Koay Weng Kuan	Received	: 17/12/2022 02:21 PM
		Report ready	: 18/12/2022 12:13 PM

TEST NAME	RESULT	FLAG	UNIT	REFERENCE	METHOD
<b>HBA1C (糖化血紅蛋白)</b>					
HbA1c (NGSP)	7.7	H	%	Normal: < 5.7 Pre-diabetes: 5.7 - 6.2 Diabetes: ≥ 6.3	Enzymatic
HbA1c (IFCC)	61	H	mmol/mol	Normal: < 39 Pre-diabetes: 39 - 44 Diabetes: ≥ 45 (Management of T2DM CPG, 6th Ed.)	Calculated
Glucose (Plasma) (血糖)	6.8		mmol/L	Fasting: < 6.1 Random: < 7.8	Hexokinase


Validated By : NURUL NADHIRAH BINTI JOHARI - BP CLINICAL LAB SDN BHD (GLENMARIE)  
Final Report Verified By : SHAHIRAH AZZAHARAH ZURAIMI - BP CLINICAL LAB SDN BHD (TAMAN MEGAH)

Page 1 of 1

Disclaimer: The above reference ranges are based on adult population unless otherwise stated. [\*] indicates age-specific paediatric reference range.

For diagnostic purposes, all laboratory test results should be used in conjunction with clinical evidence.  
For further confirmation, please repeat test with another fresh specimen, if desired.  
Should you have further enquiries, please contact your nearest BP branch or mail us at bphq@bphealthcare.com  
BP Healthcare Group @ Glenmarie, Temasya @ Glenmarie, Jalan Pendaftar U1/54, Section U1, Shah Alam, Selangor, Malaysia

# HbA1c- BEFORE

Name **Mr. Deepak Moghe** Age / Sex 58 Yrs. M /   
 Ref. By Dr. Mrs. Mardikar MD Sample ID No. 4 2005254  
 Sample Rec/Coll. Dt **25/05/2020**  
 Sample Rec/Coll Time 7:17:00 AM Type of Sample EDTA Blood, EDTA BLOOD FASTING, Seru  
 Recd. From Outside Yes

## HAEMATOLOGY

Test Name	Value	Unit	Biological Ref. Interval
-----------	-------	------	--------------------------

### HbA1c (GLYCOSYLATED HAEMOGLOBIN)

Investigation	Results	Interpretation
<b>HbA1c % :-</b>	<b>11.45 %</b>	Non diabetic : 4.3 - 5.7 % Prediabetic : 5.7-6.3 % Good diabetic control : 6.3 - 7.3 % Fair control : 7.3 - 8.3 % Poor control : 8.3 % & above

### Method :- Nephelometry & Turbidometry Done on MISPA -i<sub>2</sub>

**Note** :- \* HbA1c (Or GlycoHb) is made by post synthetic modification of Haemoglobin A at a slow rate directly dependant on blood glucose concentration during the 120 day life span of RBC.HbA1c levels may double or even triple in diabetics, depending on level of hyperglycemia, and correlate well with control of diabetes.

## BIOCHEMISTRY

Biochemistry done on VITROS 250 Dry Chemistry Analyzer

Test Name	Value	Unit	Biological Ref. Interval
BLOOD SUGAR FASTING	173	mg/dl	74 - 106
BLOOD SUGAR FASTING	160	mg/dl	74 - 106

## IMMUNOLOGY

Test Name	Value	Unit	Biological Ref. Interval
-----------	-------	------	--------------------------

Contd...2

# HbA1c- AFTER

Name **Mr. Deepak Moghe**  
Ref. By Dr. SELF  
Sample Rec/Coll. Dt **14/06/2020**  
Sample Rec/Coll Time 12:50:07

Age / Sex M /  
Sample ID No. 19



Type of Sample EDTA Blood, EDTA BLOOD RANDOM, F  
Recd. From Outside Yes

## LIVER FUNCTION TEST (LFT)

Test Name	Value	Unit	Biological Ref. Interval
VITROS 250 Dry Chem. Analyzer			
TOTAL PROTEIN	8.6	gm/dl	6.3 - 8.2
ALBUMIN	4.70	gm/dl	3.5 - 5.0
GLOBULIN*	3.90	gm/dl	2.0 - 4.0
SGOT	26	U/L	17 - 59
SGPT	34	U/L	21 - 72
ALKALINE PHOSPHATASE	83	U/L	38 - 126
BILIRUBIN TOTAL	0.7	mg/dl	0.2 - 1.3
DIRECT BILIRUBIN ( BC )	0.4	mg/dl	0.0 - 0.30
INDIRECT BILIRUBIN ( BU )	0.30	mg/dl	0.1 - 1.1

### LFT INTERPRET

## HAEMATOLOGY

### HbA1c (GLYCOSYLATED HAEMOGLOBIN)

Investigation	Results	Interpretation
<b>HbA1c % :-</b>	<b>9.0 %</b>	Non diabetic : 4.3 - 5.7 % Prediabetic : 5.7-6.3 % Good diabetic control : 6.3 - 7.3
%		Fair control : 7.3 - 8.3 % Poor control : 8.3 % & above

Method : HPLC (Done By HB-VARIO from ERBA )

Contd...4





# HbA1C- BEFORE

Bangalore Baptist Hospital  
64  
NABL  
MC-2909  
H-2011-0095

## LABORATORY REPORT


**Name** : PASTOR. LEO QUADROS  
**MRD No.** : AA733326  
**Referred By** : GENERAL(MEDICAL)  
**Lab No** : OPORD0002628769  
**Age** : 69 Year(s) 10 Month(s) 1 Day(s)  
**Sex** : Male  
**Order Date** : 09-Feb-2022 07:44:56  
**Reported on** : 09-Feb-2022 12:10:03  
**Collected Date** : 09-Feb-2022 07:50:50

Test	Result	Units	Biological Reference Interval
LDL:HDL Ratio Method : Calculation	2	Ratio	0 - 3.5
Report Verified	Yes		
<b>Blood Glucose PPBS</b> Specimen : Plasma2hr 2 hour Post Prandial (PP)Blood glucose Method : Hexokinase	331	mg/dL	80 - 140
Report Verified	Yes		
<b>BA1C</b> Glycosylated Haemoglobin (HbA1c) Specimen : EDTA Blood Sample Glycosylated Haemoglobin (HbA1c)	9.1	%	Normal - Less than 5.7% Pre-diabetes - 5.7 - 6.4% Diabetes : 6.5% and higher
Method : HPLC Method			
Report Verified	Yes		

DR. KALACHANDRABHAT, MD (P)G  
 P. No. 779/E

# HbA1C- AFTER



Visit No. : 2223AB00052873	
Name : Mr. LEO QUADROS	Reg Date : 15-Dec-2022 06:41 AM
Age / Sex : 70 Years / Male	Sample Recd On : 15-Dec-2022 06:43 AM
Ref Dr : Dr. SELF	Reported On : 15-Dec-2022 11:16 AM

### HbA1C

INVESTIGATIONS	RESULT	REF. RANGE	UNITS
GLYCOSYLATED HEMOGLOBIN (HBA1c)	7.90	Ref range Poor control : > 7.6% Fair Control : 6.8 - 7.6 % Good Diabetic Control : 5.5 - 6.8% Normal : 4.2 - 6.2%	

Method : HPLC

MEAN BLOOD GLUCOSE	180	Mean Average Blood Glucose Excellent Control : 90 - 120 mg / dL Good Control : 121 - 150 mg / dL Average Control : 151 - 180 mg / dL Action Suggested : 181 - 210 mg / dL Panic Value : >211 mg / dL	
--------------------	-----	---	--

Biorad D-10

Checked/- SUDHAKAR

**Mrs. Mani G., MSC**  
Microbiologist

*Natarajan-m*  
**Dr. M. Natarajan, MBBS, MD**  
Consultant Pathologist  
KMC NO : 34875

Diagnostic Centre : #83, N.K. Complex, Kammanahalli Main Road, Bangalore - 84, Tel : 080 25478934/65983501/25805119

Report relates to the sample tested. All reported results are for the information of the referring doctor only.  
Any difficulty in interpreting the results, kindly contact the signatory.

# HbA1C- BEFORE

**PROCESSED AT :**  
Thyrocare, Sohrabh Hall,  
112, A Wing, 1st Floor,  
Sangamwadi, Pune - 411 001

**Thyrocare**  
The Trust. The Truth.

**Corporate Office :** Thyrocare Technologies Limited D-37/3, TTC MIDC, Turbhe, Navi Mumbai - 400703  
022 - 3090 0000 / 4125 2525 8691866066 wellness@thyrocare.com www.thyrocare.com

**NAME :** RAJKUMAR HEMDEV(79Y/M)  
**REF. BY :** SELF  
**TEST ASKED :** AAROGYAM B

**SAMPLE COLLECTED AT :**  
FA 2 YUUTOPIA COMPLEX OPPOSITE RAHEJA  
GARDEN WANWORI PUNE ,

TEST NAME	TECHNOLOGY	VALUE	UNITS
HbA1c - (HPLC - NGSP Certified)	H.P.L.C	10.2	%

**Reference Range :**

Reference Range: As per ADA Guidelines

Below 5.7% : Normal  
5.7% - 6.4% : Prediabetic  
>=6.5% : Diabetic

**Guidance For Known Diabetics**

Below 6.5% : Good Control  
6.5% - 7% : Fair Control  
7.0% - 8% : Unsatisfactory Control  
>8% : Poor Control

Method : Fully Automated H.P.L.C. using Biorad Variant II Turbo, NGSP Certified.

**AVERAGE BLOOD GLUCOSE (ABG)** CALCULATED **246** mg/dl

**Reference Range :**

90 - 120 mg/dl : Good Control  
121 - 150 mg/dl : Fair Control  
151 - 180 mg/dl : Unsatisfactory Control  
> 180 mg/dl : Poor Control

Method : Derived from HbA1c values

Please correlate with clinical conditions.

**Sample Collected on (SCT)** : 06 Oct 2020 07:56  
**Sample Received on (SRT)** : 06 Oct 2020 17:23  
**Report Released on (RRT)** : 06 Oct 2020 18:43  
**Sample Type** : EDTA  
**Labcode** : 0610043934/AE847 Dr.Prachi Sinkar MD(Path)  
**Barcode** : R1402709





# HbA1C- AFTER



## K.E.M. HOSPITAL, PUNE - 11.

489, Rasta Peth, Sardar Moodliar Road.  
TEL.:020-66037300, E-mail :diagnosticsmanager@kemhospital.org



Certificate No. : M0362  
NABL Accredited Laboratory

Patient	: Mr. RAJKUMAR LALCHAND HEMDEV	PRN	: 780262	IP No.	: -
Age/Sex	: 79 Yrs/Male	Visit No.	: OP-7	Date	: 01/06/2021
Referred By	: Dr. Smita Dhadge	Sample Collected	: 01/06/2021 12:43		
Location	: OPD	Sample Recvd in Lab	: 01/06/2021 12:43		
Sponsor	: -	Reported On	: 02/06/2021 10:25		
Specimen	: Blood				
Lab No.	: 0032115221	Status	: Final		

### DEPARTMENT OF ENDOCRINOLOGY

Investigations	Result	Bio. Ref. Interval
GLYCOSYLATED HB (HB A1C)	7.900 %	NON DIABETES LESS THAN 5.7 % PRE DIABETES: 5.7 - 6.4 % DIABETES: 6.5 % OR HIGHER

Method: HPLC

-----End Of Report-----

Checked By Technician

*A.N.*  
**DR. SADANAND NAIK**  
 M.Sc.Ph.D.(Med.Biochemistry)  
 HOD-Clinical Biochemistry

Entered By:thp9686

# HbA1C- BEFORE

PROCESSED AT : Thyrocare  
D-2/21, TTC MIDC, Turbhe,  
Navi Mumbai-400 702

Corporate office : Thyrocare Technologies (India) Pvt. Ltd., TTC MIDC, Turbhe, Near Mumbai - 400 702  
☎ 022 - 8354 0000 | 8753 2600 | 8879664333 | info@thyrocare.com | www.thyrocare.com

NGSP CAP ACCREDITED Thyrocare Tests by

**REPORT**

NAME : ANUSHAGAN CHILDHAMYANI/W  
REF. BY : SELF  
TEST ASKED : EXECUTIVE FULL BODY HEALTH CHECKUP I  
PATIENT ID : ACL1731603

HOME COLLECTION : ADDRESS : 501 / 4 WING BACHUA CORP RESIDENCY BUILDING SAKINAKA 90 PTH MUMBAI PIN CODE : 400072

TEST NAME	TECHNOLOGY	VALUE	UNITS
HbA1c - (HPLC - NCEP Certified)	H.P.L.C	7.5	%

Reference Range :  
Reference Range: As per ADA Guidelines  
Below 5.7% : Normal  
5.7% - 6.4% : Prediabetic  
>=6.5% : Diabetic

Guidance For Known Diabetics  
Below 6.7% : Good Control  
6.5% - 7% : Fair Control  
7.0% - 8% : Unsatisfactory Control  
>8% : Poor Control

Method : Fully Automated HPLC using Biorad Variant II Suite

AVERAGE BLOOD GLUCOSE (ABG)	CALCULATED	149	mg/dl
-----------------------------	------------	-----	-------

Reference Range :  
90 - 130 mg/dl : Good Control  
122 - 150 mg/dl : Fair Control  
151 - 180 mg/dl : Unsatisfactory Control  
> 180 mg/dl : Poor Control

Method : Derived from HbA1c values  
Please correlate with clinical conditions.

**eMedica**

Sample Collected on (SCT) : 21 Sep 2022 08:37  
Sample Received on (SRT) : 21 Sep 2022 12:31  
Report Released on (RRT) : 21 Sep 2022 17:44  
Sample Type : EDTA  
Labcode : 2710400101/EP004  
Barcode : 24590440

Dr. Hukdeep Singh MD(Paths)  
Dr. Sachin I  
Page : 18 of



# HbA1C- AFTER

**PROCESSED AT :**  
Thyrocare  
D-37/1, TTC MIDC, Turbhe,  
Navi Mumbai-400 703

**Corporate Office:** Thyrocare Technologies Limited, D-37/1, TTC MIDC, Turbhe, Navi Mumbai - 400 703  
(0) 22- 2690 8888 / 4712 3488 | 02269082333 | info@thyrocare.com | www.thyrocare.com

**REPORT**

**NAME :** ARUNHASAN CHIDHARICHRU  
**REF. BY :** SELF  
**TEST ASKED :** EXECUTIVE FULL BODY HEALTH CHECKUP I

**PATIENTID :** AC11731802

**HOME COLLECTION :**  
302 JA WING DDOUGLA COMPLEX REGENCY  
REDDING SARANGA 30 FEET ROAD MUMBAI 40  
CODE -400012

TEST NAME	TECHNOLOGY	VALUE	UNITS
HbA1c - (HPLC - NGSP Certified)	H.P.L.C	6.7	%

**Reference Range :**

Reference Range: As per ADA Guidelines	Guidance For Known Diabetics
Below 5.7% : Normal	Below 6.5% : Good Control
5.7% - 6.4% : Prediabetic	6.5% - 7% : Fair Control
≥6.5% : Diabetic	7.0% - 8% : Unsatisfactory Control
	>8% : Poor Control

**AVERAGE BLOOD GLUCOSE (ABG)**

Reference Range :	CALCULATED	UNITS
90 - 120 mg/dl : Good Control	146	mg/dl
121 - 150 mg/dl : Fair Control		
151 - 180 mg/dl : Unsatisfactory Control		
> 180 mg/dl : Poor Control		

**Sample Collected on (SCT)** : 23 Oct 2022 08:55  
**Sample Received on (SRT)** : 23 Oct 2022 16:49  
**Report Released on (RRT)** : 23 Oct 2022 23:37

**Sample Type** : EDTA  
**Labcode** : 2310000776/FP004  
**Barcode** : AH252658

Dr. Kuldeep Singh MD

15 / 20

Page : 15 of 20





# Creatinine - BEFORE

Medical Laboratory Report

35



<b>Patient Information</b> Name : Mr.ASHOK SAINI Age/Gender : 72Y 2M 3D/Male MobileNo : 9892697751 UHID : LDAA00031381 Address : 1102 tulip, dosti acre, behind antop hill bus depot. 400037	<b>Specimen Information</b> Visit ID : LDAL442 Collected : 24/Apr/2022 08:02 Received : 24/Apr/2022 15:41 Reported : 24/Apr/2022 16:33 IP/OP/Barcode : Report Status : Final Report	<b>Client/ Doctor Information</b> Ref Doctor : Dr.SELF Client Code : LMPCC0121 Client Add. : WADALA EAS Client No. : Client Name : PCC WADALA DOSTI ACRES
---	---	--

Test Name	Result	Bio. Ref. Range	Unit	Method
-----------	--------	-----------------	------	--------

**Blood Urea Nitrogen (BUN) , SERUM**

Blood Urea Nitrogen (BUN)	57.4	8.0-23.0	mg/dl	Kinetic Urease
Result Rechecked				

**Creatinine, Serum**

Creatinine	6.78	0.70-1.20	mg/dL	Kinetic Jaffe
Result Rechecked				

**Electrolytes, Serum**

Sodium	140.2	136 - 145	mmol/L	Ion-selective electrode
Potassium	5.7	3.4 - 5.1	mmol/L	Ion-selective electrode
Chloride	105.5	98-107	mmol/L	Ion-selective Electrode
Result Rechecked				

Page 1 of 2



SIN No:BI00078018

This test has been performed at Lupin Diagnostics Laboratory, NRL, MUMBAI National Reference Laboratory, Plot No.C-533, MIDC, TTC Industrial Area, Pawane

Registered and Corporate Office:

35

Lupin Healthcare Limited, 3rd Floor, Kalpataru Inspire, Off W. E. Highway, Santacruz (East), Mumbai - 400 055, India. | CIN : U24100MH2011PLC214885



# Creatinine - AFTER

36 36

<b>Patient Information</b>	<b>Specimen Information</b>	<b>Client/ Doctor Information</b>
Name : Mr.ASHOK SAINI	Visit ID : LDAL715	Ref Doctor : Dr.SELF
Age/Gender : 71Y 3M 9D/Male	Collected : 09/Jun/2022 09:42	Client Code : LMPCC0121
MobileNo : 989269775 1	Received : 09/Jun/2022 12:17	Client Add. : WADALA EAS
UHID : LDAA00039220	Reported : 09/Jun/2022 13:49	Client No. :
Address : 1102 Dosti Tulip Dosti Acres	IP/OP/Barcode :	Client Name : PCC WADALA DOSTI ACRES
	Report Status : Final Report	

Test Name	Result	Bio. Ref. Range	Unit	Method
-----------	--------	-----------------	------	--------

**Blood Urea Nitrogen (BUN) , SERUM**

Blood Urea Nitrogen (BUN)	50.1	8.0-23.0	mg/dl	Kinetic Urease
---------------------------	------	----------	-------	----------------

**Creatinine, Serum**

Creatinine	6.07	0.70-1.20	mg/dL	Kinetic Jaffe
Result Rechecked				


**Electrolytes, Serum**

Sodium	134.0	136 - 145	mmol/L	Ion-selective electrode
Potassium	5.2	3.4 - 5.1	mmol/L	Ion-selective electrode
Chloride	106.9	98-107	mmol/L	Ion-selective Electrode






# Creatinine - BEFORE




**BIOCHEMISTRY**

Patient Name <b>Mrs. PUSHPA CHAUHAN</b>		Age <b>55Yr 10Mth 13Days</b>	Gender <b>Female</b>
UHID <b>ANM1.0000188209</b>	SIN \ LRN <b>2221545 \ 945046</b>	Specimen <b>Serum</b>	
WIBNo/RefNo <b>OP</b>	Received on <b>24-MAY-2021 03:50:35 PM</b>	PatSer No. <b>ANMOPP981612</b>	
Collected on <b>24-MAY-2021 03:12:06 PM</b>	Reported on <b>24-MAY-2021 04:55:00 PM</b>	Ref Doctor <b>Dr. MAHESH UPARKAR</b>	



TEST NAME	RESULT	BIOLOGICAL REFERENCE INTERVALS	UNITS
CREATININE - SERUM / PLASMA CREATININE - SERUM / PLASMA Method : Modified Jaffe reaction.	<b>7.63 *</b>	Female: 0.6 - 1.1	mg/dL




The OTP will be sent ONLY to registered phone number of the patient as per hospital records (Note patient phone may be different from registered phone)

Report Status: Final \* END OF REPORT \*

CHECKED BY 1062110  
1060110

Printed On: 26-MAY-2021 01:03:17 PM



Dr Vishal Mehrotra  
Head - Laboratory Services  
Consultant Haematology & Clinical Pathology

Page 1 of 1

For enquires, appointments contact: **022 - 3350 3350**

Apollo Hospitals Enterprise Limited, No. 19, Bishop Gardens, Raja Annamalaipuram, Chennai - 600 028, CIN: LB5110TN1979PL008035



# Creatinine - AFTER

**DIAGNOSTICS REPORT**

CLIENT CODE : CD00077515  
 CLIENT'S NAME AND ADDRESS :  
 SRL PSC SEAWOODS WALK-IN  
 LAXMI ICON, SHOP NO.-10, PLOT NO.-69-70, SECTOR-44 A,  
 SEAWOODS,  
 NAVI MUMBAI 400706  
 MAHARASHTRA INDIA  
 9136130099

Barcode: Patient Ref. No. 4000R000750409

SRL Ltd  
 BHOOMI TOWER, 1ST FLOOR, HALL NO.1, PLOT NO.28 SECTOR 4,  
 KHARGHAR  
 NAVI MUMBAI, 410210  
 MAHARASHTRA, INDIA  
 Tel : 9111591115, Fax :  
 CIN - U74899PB1995PLC045956

PATIENT NAME : **PUSHPA CHAUHAN**  
 AGE : 54 Years SEX : Female  
 ACCESSION NO : **0040UI000194** PATIENT ID : **PUSHF992978540**  
 DRAWN : **01/09/2021 11:52** RECEIVED : 01/09/2021 13:20  
 REFERRING DOCTOR : DR. RAVINDRA NIKALJI REPORTED : 02/09/2021 14:33

Test Report Status **Final** Results Biological Reference Interval Units

**KIDNEY PANEL - 1**

**SERUM BLOOD UREA NITROGEN**  
 BLOOD UREA NITROGEN  
 METHOD : LIASE - UV  
 57 High 6 - 20 mg/dL

Date	Value (mg/dL)
04-MAY-2018	62
21-SEP-2018	50
01-SEP-2021	57

**CREATININE, SERUM**  
**CREATININE** 6.00 High 0.50 - 0.90 mg/dL  
 METHOD : JAFEE METHOD

Page 1 Of 8





# Creatinine - BEFORE

**Medicare Hospital & Research Centre**  
 4/5, Ravindra Nagar, Old Palasia, INDORE-452 018 (M.P.)  
 Ph.:0731-4271600, 2490577, 2492621, 4065616-17-18 • Fax : 4266243  
 Mobile : 88899-12611, E-mail : medicarehospitalindore@gmail.com  
 Website : www.medicarehospitalindore.com




- PATHOLOGY
- MICROBIOLOGY
- BIOCHEMISTRY
- BLOOD BANK

**Patient Name :** Mrs. UMA SARAF [MRN-210800808]  
**Age / Gender :** 72 Yr / Female  
**Address :** BEEMA NAGAR, Indore, MADHYA PRADESH  
**Req. Doctor:** Self  
**Regn. ID:** WALKIN.21-22-5396

### BIOCHEMISTRY

**Request Date :** 09-08-2021 11:08 AM      **Reporting Date :** 09-08-2021 12:40 PM  
**Sample No. :** BI2442      **Reporting Status :** Finalized  
**Acceptance Date :** 09-08-2021 11:56 AM

INVESTIGATIONS	RESULT	REFERENCE RANGE
<b>CREATININE</b>	<b>4.9 mg/dL *</b>	0.50 - 1.40 mg/dL
<b>BLOOD UREA NITROGEN *[ SERUM ]</b>		
Blood Urea	92 mg/dL *	20.00 - 40.00 mg/dL
Blood Urea Nitrogen (BUN)	42.99 mg/dL *	6.00 - 20.00 mg/dL
<b>POTASSIUM.</b>	<b>5.2 Meq/L *</b>	3.50 - 5.00 Meq/L

END OF REPORT.

*K.S. Rajani*

Dr. Karamchand Rajani  
D.C.P (London)

*Chandrashekhar*

Dr. Chandrashekhar  
(MD,Pathology)

*Pradeep Apte*

Dr. Pradeep Apte  
(M.Sc,DSM,Ph.D)



Mrs. UMA SARAF / MRN-210800808  
Regn No.: WALKIN.21-22-5396



www.emedica.in  
info.emedica@gmail.com

# Creatinine - AFTER

**Medicare Hospital & Research Centre**  
 4/5, Ravindra Nagar, Old Palasia, INDORE-452 018 (M.P.)  
 Ph.:0731-4271600, 2490577, 2492621, 4065616-17-18 • Fax : 4266243  
 Mobile : 88899-12611, E-mail : medicarehospitalindore@gmail.com  
 Website : www.medicarehospitalindore.com

**U-LAB**  
 • PATHOLOGY  
 • MICROBIOLOGY  
 • BIOCHEMISTRY  
 • BLOOD BANK

**Patient Name :** Mrs. UMA SARAF [MRN-210800808]  
**Age / Gender :** 72 Yr / Female  
**Address :** BEEMA NAGAR, Indore, MADHYA PRADESH  
**Req. Doctor :** SELF  
**Regn. ID:** WALKIN.21-22-17438

### BIOCHEMISTRY

**Request Date :** 20-10-2021 06:51 AM      **Reporting Date :** 20-10-2021 11:20 AM  
**Sample No. :** BI6961      **Reporting Status :** Finalized  
**Acceptance Date :** 20-10-2021 11:20 AM

INVESTIGATIONS	RESULT	REFERENCE RANGE
CREATININE	4.3 mg/dL *	0.50 - 1.40 mg/dL
GLUCOSE (FASTING)	76 mgm%	70.00 - 110.00 mgm%

END OF REPORT.

*KS Rajani*  
 Dr. Karamchand Rajani  
 D.C.P. (London)

*Chandrashekhar*  
 Dr. Chandrashekhar  
 (MD, Pathology)


*Pradeep Apte*  
 Dr. Pradeep Apte  
 (M.Sc, DSM, Ph.D)



Mrs. UMA SARAF / MRN-210800808  
 Regn. No.: WALKIN.21-22-17438



# Creatinine - BEFORE




**Vision Diagnostics**  
Leading Technology in Advanced Diagnosis  
Associated NABL laboratory

NAME : <b>Mr. RAJA VARMA</b>	REG/LAB NO. : 22080076 / 2691049
AGE/SEX : 62 Yrs / Male	DATE OF REPORT : <b>02-08-2022</b> at 04:06 PM
REFERRED BY :	BILL NO. : 078189
REF. CENTER : NEPHROPLUS	

TEST PARAMETER	RESULT	NORMAL RANGE
<b>HAEMATOLOGY</b>		
HAEMOGLOBIN	10.3 gm/dl	14 - 18 gm/dl
<b>BIOCHEMISTRY</b>		
<b>ALBUMIN</b>		
SERUM ALBUMIN	4.4 g/dl	3 - 5 g/dl
BLOOD UREA	102 mg/dL	10 - 50 mg/dL
SERUM CALCIUM	9.0 mg/dL	8.5 - 10.3 mg/dL
<b>SERUM CREATININE</b>	<b>6.1 mg/dL</b>	Adults : 0.6 - 1.4 mg/dl Child 0-2yrs : 0.2 - 0.6 mg/dl 3-8yrs : 0.3 - 0.8 mg/dl
SERUM PHOSPHORUS	4.7 mg/dl	2.1 - 5.6 mg/dl
S.POTASSIUM(K <sup>+</sup> )	4.98 mmol/L	3.5 - 5.5 mmol/L
S.SODIUM	136 mmol/L	135 - 155 mmol/L
SGOT	18 U/L	2 - 40 U/L
SGPT	21 U/L	2 - 40 U/L

Dispatched by: Santhosh
End of Report \*\*\*\*
Printed by: Santhosh on 02-08-2022 at 04:06 PM

  
**Dr. Shruthi**  
 Consulting Pathologist

Page 1 of 1

#44, Pipeline Main Road, Vijayanagar, Bengaluru-40  
 E-mail : visiondiagnosticss@gmail.com, Ph : 080-2340 4871, Mob : 98807 82516

# Creatinine - AFTER

**Vision Diagnostics**  
Leading Technology in Advanced Diagnosis .....  
Associated NABL laboratory

NAME : **Mr. RAJA RAJA VARMA**      REG/LAB NO. : 22090031 / 2692149  
AGE/SEX : 62 Yrs / Male      DATE OF REPORT : **01-09-2022** at 04:38 P.  
REFERRED BY :      BILL NO. : 079289  
REF. CENTER : NEPHROPLUS

TEST PARAMETER	RESULT	NORMAL RANGE
<b>HAEMATOLOGY</b>		
HAEMOGLOBIN	10.0 gm/dl	14 - 18 gm/dl
<b>BIOCHEMISTRY</b>		
<b>ALBUMIN</b>		
SERUM ALBUMIN	4.3 g/dl	3 - 5 g/dl
BLOOD UREA	89 mg/dL	10 - 50 mg/dL
SERUM CALCIUM	8.8 mg/dL	8.5 - 10.3 mg/dL
SERUM CREATININE	5.7 mg/dL	Adults : 0.6 - 1.4 mg/dl Child 0-2yrs : 0.2 - 0.6 mg/dl 3-8yrs : 0.3 -0.8 mg/dl
SERUM PHOSPHORUS	4.5 mg/dl	2.1 - 5.6 mg/dl
S.POTASSIUM(K <sup>+</sup> )	4.32 mmol/L	3.5 - 5.5 mmol/L
S G O T	20 U/L	2 - 40 U/L
S G P T	16 U/L	2 - 40 U/L
S.SODIUM	132 mmol/L	135 - 155 mmol/L

Dispatched by: Sarthosh      \*\*\*\* End of Report \*\*\*\*      Printed by: Sarthosh on 01-09-2022 at 04:38

*Shruthi H*  
**Dr. Shruthi H**  
Consulting Pathologist

Page 1 of 1

#44, Pipeline Main Road, Vijayanagar, Bengaluru-40  
E-mail : visiondiagnostics@gmail.com, Ph : 080-2340 4871, Mob : 98807 62516



# Thyroid - BEFORE

**DIAGNOPEIN**  
 Diagnosis For A Better Tomorrow  
 ISO 9001:2015 Certified Lab

38210400014

Bill No. : 63232  
 Patient Name : **MRS. MONIKA S. DESARDA**  
 Age/Sex : 40 / Female  
 Center : DIAGNOPEIN, BIBWEWADI  
 Referred By. : SELF

PID : 31137  
 Registration : 15/02/21, 08:14 AM  
 Reported : 15/02/21, 02:32 PM  
 Status : Final Report

Investigation	Result	Units	Bio.Ref. Interval
<b>IMMUNOASSAY</b>			
<b>TFT - THYROID FUNCTION TEST</b>			
Tri-iodothyronine, Total (T3)	1.139	ng/ml	0.60 - 2.15
Thyroxine, Total (T4)	85.59	ng/ml	52 - 127
Method : (Serum, CLIA) <b>Ultra TSH</b>	<b>10.05</b>	uIU/mL	0.3 - 4.5
Method : (Serum, CLIA)			

**Note:**  
 Reference ranges are age dependent and somewhat method dependent, the above values are approximate expected values. Reference range for Pregnant women are as per American Thyroid Association guidelines. T3 & T4 levels may be abnormal in euthyroid sick syndrome. Physiological rise in Total T3 / T4 levels is seen in pregnancy and in patients on steroid therapy. TSH may be the only parameter abnormal in subclinical hypothyroidism. Many drugs and intercurrent illnesses are associated with alterations in serum TSH. Hence all results should be clinically correlated and if required repeated when patient is clinically stable.



# Thyroid - AFTER



Bill No.	: 87471	PID	: 31137
Patient Name	: MRS. MONIKA S. DESARDA	Registration	: 15/04/21, 09:01 AM
Age/Sex	: 40 / Female	Reported	: 15/04/21, 01:44 PM
Center	: DIAGNOPEIN,BIBWEWADI	Status	: Final Report
Referred By.	: SELF		

Investigation	Result	Units	Bio.Ref. Interval
<b>IMMUNOASSAY</b>			
<b>TFT - THYROID FUNCTION TEST</b>			
Tri-iodothyronine, Total (T3)	1.173	ng/ml	0.60 - 2.15
Thyroxine, Total (T4)	93.59	ng/ml	52 - 127
Method : (Serum, CLIA)			
<b>Ultra TSH</b>	<b>3.824</b>	uIU/mL	0.3 - 4.5
Method : (Serum, CLIA)			

**Note:**  
Reference ranges are age dependent and somewhat method dependent, the above values are approximate expected values. Reference range for Pregnant women are as per American Thyroid Association guidelines. T3 & T4 levels may be abnormal in euthyroid sick syndrome. Physiological rise in Total T3 / T4 levels is seen in pregnancy and in patients on steroid therapy. TSH may be the only parameter abnormal in subclinical hypothyroidism. Many drugs and intercurrent illnesses are associated with alterations in serum TSH. Hence all results should be clinically correlated and if required repeated when patient is clinically stable.

\*\*END OF REPORT\*\*

Checked by - Prasad

*Payal*  
Dr. Payal Kalwar  
M.D. Pathologist

# Heart - BEFORE



## NOBLE HOSPITALS, PUNE

South East Pune's 1st NABH Accredited Hospital

153, Magarpatta City Road, Hadapsar, Pune 411 013. Tel.: 020-6628 5000 Fax : 020 - 6628 5199  
CIN NO. U8510PN1996PTC103171, Visit Us at : www.noblehospitalspune.com

Mark of Excellence



National Accreditation Board  
for Hospital and Healthcare Providers

### DEPARTMENT OF CARDIOLOGY

10<sup>th</sup> FEB, 2021

MRS.BHUTADA SHOBHA.

#### CORONARY ANGIOGRAPHY REPORT.

LEFT MAIN : Distal 60 % stenosis.

LEFT ANTERIOR DESCENDING CORONARY : Mid LAD 85-90 % stenosis.  
diffuse disease poor target.

LEFT CIRCUMFLEX CORONARY ARTERY. : OM,90 % calcific stenosis.  
Moderately calcified.

RIGHT CORONARY : Proximal 60 % stenosis.  
Mid RCA diffuse disease  
RPDA 90 % stenosis.

RECOMMENDATION : **Surgical opinion.**

for  
Dr. RAHUL SAWANT  
MD MRCP (UK)  
CCT (Cardiology) UK,  
Interventional Fellow, New York, USA.  
Consultant Interventional Cardiologist.



Dr Rahoul D Sawant  
MD (Medicine)  
CCT, Cardiology (UK), MRCP (UK), FACC (USA)  
Interventional Fellow, New York, USA  
Consultant Interventional Cardiologist  
MMC Reg. No. : 85360  
Asst. Professor, Cardiology, BVMCH, Pune

2998 : Mrs.Bhutada Shobha (60y, Female)

Date: 03-Feb-2021

BP 159 / 119<sup>+</sup> mmHg Pulse 88 bpm Height 158 cm Weight 64.9 kg Temperature 97.2 F SPO2 98 % BMI 26.00 Kg/m<sup>2</sup>

**Complaints:** SOB ON EXERTION CLASS 3, PND

**Diagnosis:** DM , HTN

**Sys.Exam:** CVS: ECG: SR. T wave inversion in lateral leads.

2DECHO:  
AO 20 LA 36 IVS 14 PW 14 LV D42 LV S 28  
E/A 1.49

**RVSP 32 +10 mm of Hg.**

Normal size LV with moderate to severely impaired LV function.  
Anterior wall, lateral wall, apex and distal septum are severely hypokinetic.

**EF 30%**

Rheumatic involvement of mitral valve. AML mildly thickened and PML movement is restricted.  
moderate to severe MR

Aortic valve is normal

Mild TR, Mild PH.; General: F 203 PP 336

Lipid Profile: TC-173, TRG-115, HDL-19, LDL-130, NonHDL-153, TC/HDL Ratio:9.0, BSL-183mg.;

## Heart - AFTER



**Dr Rahoul D Sawant**  
MD (Medicine)  
CCT, Cardiology (UK), MRCP (UK), FACC (USA)  
Interventional Fellow, New York, USA  
Consultant Interventional Cardiologist  
MMC Reg. No. : 85360  
Asst. Professor, Cardiology, BVMCH, Pune

2998 : Mrs.Bhutada Shobha (61y, Female)

Date: 01-May-2021

BP 160 / 84\* mmHg Pulse 67 bpm Height 160 cm Weight 58.7 kg Temperature 97.2 F SPO2 98 % BMI 22.93 Kg/m<sup>2</sup>

**Complaints:** FLUCTUATING BSL, NO CHEST PAIN OR SOB

**Diagnosis:** DM , HTN , EF 30% , CAG 10.02.20201 TVD FOR SURGICAL OPINION , CREAT 1.28

**Sys.Exam:** CVS: ECG: SR. ST T changes in lateral leads.

2DECHO:

Ao 20 LA 37 IVS 12 PW 12 LV D 41 LV S 29

Normal LV size and mildly impaired LV systolic function.

EF 45%. EF has improved significantly.

Rheumatic involvement of mitral valve. AML thickened. PML movement restricted.


moderate MR

Normal aortic valve.

Mild TR. RVSP 15 + 10 mm of Hg.;



# Heart - BEFORE



erlina Hospitals | 20+ years | sterlina Hospitals

20+ years | sterlina Hospitals  
Hope • Health • Happiness | Because life matters

PATIENT'S NAME : Mr. Bobby Singh Poonia (38 Years/Male)  
DATE OF ANGIO : 8<sup>th</sup> July, 2022  
ANGIO NO. : E - 12448  
IP No : 1217815

**REPORT OF CORONARY ANGIOGRAPHY**

AO PRESSURE : 120/80 mm of Hg

Procedure was done via Right Radial Artery.

LMCA : Normal

LAD : 99% long lesion in mid part

DIAGONAL : 75% lesion

LCX : 40% proximal lesion, OM1 - 80% lesion  
OM2 - 75% - 80% multiple lesions  
OM3 - 100% lesion

RCA : 85% mid lesion followed by 100% lesion.  
Distal part in filled by collaterals from LCA.

LV Angio : Not done

FINAL DIAGNOSIS :  
➤ CORONARY ARTERY DISEASE - CRITICAL TRIPLE VESSEL DISEASE  
➤ ACUTE CORONARY SYNDROME

RECOMMENDATION : EARLY REVASCULARIZATION

Dr. Rasesh Pothiwala MD, DNB (Cardiologist) Head of the Department  
Dr. Akash Ramchandani MD, DM (Cardiologist)  
Dr. Rahul Joshi (Cardiac Associate)

Prepared by: Sagar Prajapati



🌐 [www.emedica.in](http://www.emedica.in)  
✉ [info.emedica@gmail.com](mailto:info.emedica@gmail.com)

# Heart - AFTER

DD1 Job ID – 8723186  
K953598/418 675 7658

**NHS**  
University Hospitals Birmingham  
NHS Foundation Trust

This gentleman does have a surgical pattern of coronary artery disease. However, he is having minimal symptoms at present. Therefore, after discussion with him, we are opting to treat him medically in the first instance. We have started him on Bisoprolol 1.25 mg once daily which I would be grateful if you could continue. He will have a routine follow up with Dr Khan and if his symptoms become more intrusive then he will be referred for coronary artery bypass grafting.

Yours sincerely



**Electronically approved**  
  
**Dr Ashwin Radhakrishnan**  
ST7 Cardiology

ICC:  
Dr Paul Jordan  
Consultant Cardiologist  
QEH



# Eyes Refraction Error - BEFORE



Name : **Mr. RAJKUMAR HAEMDEV**  
MR No : 00001010/PUNE  
Ref by :

Date : **16/Apr/2015**  
Age/Sex : **Male**

### VISIT REPORT

**Complaints** : FOR RETINAL EVALUATION & MANAGEMENT USING SPECTS SINCE THE AGE OF 20YRS -

**History** : DM SINCE 45YRS ON RX, BORN WITH HERNIA-NOT OPERATED

<u>On Examination</u>	<u>Right Eye</u>	<u>Left Eye</u>
BCVA	6/9 N/6	6/6 N/6
K'metry (AutoK)	KH : 41.25/8.20X1 KV : 40.75/8.26X91	KH : 41.00/8.22X4 KV : 41.25/8.17X94
Autoref	+0.25/-0.50X70	-0.25/-1.00X13
IOP	17mmHg	15mmHg
Slit Lamp Exam.	NS 1	NS 1
Fundus	MODERATE NPDR	MODERATE NPDR

**Advice** :  
TAB MACUGOLD ONCE A DAY FOR 3 MONTH  
EYE DROPS REFRESH TEARS 3 TIMES A DAY A MONTH

	Right Eye				Left Eye			
	Sph	Cyl	Axis	VA	Sph	Cyl	Axis	VA
Dist	-0.50	-0.75	70	6/9	0.00	-1.00	10	6/6
Near Add	+2.50			N/6	+2.50			N/6

*[Signature]*  
**Dr VARDHAMAN Kankariya**







# Eyes Refraction Error - AFTER

**Dr. Agarwals**  
 Eye Hospital  
 For eyes like new

31/1, Kutika, Pune - Solapur Road, Hadapsar,  
 Pune - 411013  
 Call: 7338987777  
 GST No.: 33AAACD2373G1Z2

Patient : **MR. RAJKUMAR HEMDEV**  
 Age/Sex : 79 Years /Male  
 Contact : 9823338118  
 MR No. : HDP/4725/20

Doctor : **Dr. MAHESH PATHAK**  
 Facility : Dr Agarwal's Eye Hospital-HDP  
 Appt. Dt : 24 Nov'20  
 Note Dt : 24 Nov'20

### OPD SUMMARY

#### HISTORY

WANT FULL EYE CHECKUP  
 Known cases of OU CAT SX DONE 1 YEAR BACK , Diabetes since 40 years - on medication , Hypertension since 40 years - ON MEDICATION .

#### ASSES PRESCRIPTIONS

	R/OD				L/OS			
	Sph	Cyl	Axis	Vision	Sph	Cyl	Axis	Vision
Distant	+0.00	--	--	6/6-2	0.00	--	--	6/6P
Near	<b>+1.75</b>	--	--	N6	<b>+1.75</b>	--	--	N6

#### REFRACTION



# Leukaemia - BEFORE

**Patient** : Mrs. RUKMINI SHROFF  
**Age/Sex** : 62 Yrs/Female  
**Referred By** : Dr. Shashikant Apte  
**Location** : OPD  
**Sponsor** : -  
**Collected At** : Sahyadri Speciality Hospitals  
**Lab No.** : 0031503118  
**PRN** : 867007  
**Visit No.** : OP-2  
**Sample Collected** : 31/01/2018 11:00  
**Sample Rcvd. in Lab** : 31/01/2018 11:53  
**Reported On** : 31/01/2018 15:56  
**Processed At** : SSL Main Lab  
**Status** : Verified  
**IP No.** : -  
**Date** : 31/01/2018

## HAEMOGRAM

Specimen : EDTA Whole Blood

Test Name	Test Value	UOM	Biological Reference Interval
Haemoglobin	10.9	g/dL	12.0 - 15.0
R.B.C. Count	3.26	x 10 <sup>6</sup> /ul	3.80 - 4.80
Haematocrit	31.6	%	36.0 - 46.0
M.C.V.	96.9	fl	76 - 96
M.C.H	33.6	pg	27 - 32
M.C.H.C.	34.7	gm/dl	31.5 - 34.5
R.D.W. -CV	18.7	%	11.6 - 14
Total W.B.C. Count	175600	/uL	4000 - 10000
<b>Differential Count</b>			
Blast	5	%	
Myelocytes	8	%	
Meta+Band	9	%	
Neutrophils	63.0	%	40.0 - 80.0
Lymphocytes	6.0	%	20.0 - 40.0
Monocytes	2.0	%	2.0 - 10.0
Eosinophils	4.0	%	1.0 - 6.0
Basophils	3.0	%	< 1 - 2
Platelet Count	198000	/uL	150000 - 410000
MPV	10.3	fl	

### Smear Study

Marked neutrophilic leucocytosis with shift to left upto blasts (5%).  
 Normocytic normochromic anemia, anisocytosis +.  
 Platelets adequate on smear.

Performed on Beckman Coulter Haematology Analyzer.

End Of Report

# Leukaemia - AFTER

## Sahyadri Speciality Labs

e-mail : labinfo@sahyadrihospitals.com www.sahyadrihospital.com



<b>Patient</b> : Mrs. RUKMINI SHROFF	<b>PRN</b> : 867007	<b>IP No.</b> :-
<b>Age/Sex</b> : 63 Yrs/Female	<b>Visit No.</b> : OP-8	<b>Date</b> : 26/10/2018
<b>Referred By</b> : Dr. Shashikant Apte	<b>Sample Collected</b> : 26/10/2018 11:59	
<b>Location</b> : OPD	<b>Sample Rcvd. in Lab</b> : 26/10/2018 12:46	
<b>Sponsor</b> :-	<b>Reported On</b> : 26/10/2018 14:35	
<b>Collected At</b> : Sahyadri Speciality Labs	<b>Processed At</b> : SSL Main Lab	
<b>Lab No.</b> : 0057229918	<b>Status</b> : Verified	

### HAEMOGRAM

Specimen : EDTA Whole Blood

Test Name	Test Value	UOM	Biological Reference Interval
Haemoglobin	10.0	g/dL	12.0 - 15.0
R.B.C. Count	3.24	$\times 10^6/\mu\text{l}$	3.80 - 4.80
Haematocrit	31.3	%	36.0 - 46.0
M.C.V.	96.5	fL	76 - 96
M.C.H	31	pg	27 - 32
M.C.H.C.	32.1	gm/dl	31.5 - 34.5
R.D.W. -CV	16.6	%	11.5 - 14
<b>Total W.B.C. Count</b>	<b>7300</b>	$/\mu\text{L}$	4000 - 10000
<b>Differential Count</b>			
Neutrophils	69.7	%	40.0 - 80.0
Lymphocytes	21.5	%	20.0 - 40.0
Monocytes	3.9	%	2.0 - 10.0
Eosinophils	4.5	%	1.0 - 6.0
Basophils	0.4	%	< 1 - 2
<b>Platelet Count</b>	<b>323000</b>	$/\mu\text{L}$	150000 - 410000
MPV	8	fL	

**Smear Study** Normocytic normochromic RBCs.  
Platelets adequate on smear.

Performed on Beckman Coulter Haematology Analyzer.

-----End Of Report-----



Dr. Rajesh Phatale  
M.B.B.S., M.D. (Pathology)  
Reg. No: 67843

Entered By:70000971

